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The Impact of Blockchain Technology on Clinical Trial Data Integrity 
Abstract 
Karl Cullen 
In this study it was shown how a new and emerging technology known as Blockchain, a data 
management platform, possesses the potential to address some of the predominant issues 
pertaining to clinical data integrity within clinical trial research studies. However, many obstacles 
and challenges persist with its implementation and these must be addressed, understood and 
solved before the technology can be utilized to manage clinical data. The main research objective 
of this study was to examine how Blockchain could be suited to address the concerns relating to 
clinical data integrity and to address the perceptions of participants involved with clinical data 
management to the technology and its potential application within clinical trials. Through an 
exploratory quantitative and qualitative mixed methods approach aligned with a pragmatist 
research philosophy, primary data was collected from participants who were purposively selected 
from a homogenous sampling pool that consisted of those with backgrounds in clinical data 
management. Primary data produced from this study highlighted the correlation of data issues that 
contribute towards the lack of integrity of clinical data with those found in secondary research. It 
was also found that the perception of Blockchain was generally positive and favorable towards 
its adoption within clinical trials. However, there was a degree of uncertainty surrounding the 
security of data within Blockchain. Various challenges were identified, primarily, the complexity 
of the technology and challenges related to compliancy with data protection laws. The conclusive 
determination of Blockchain’s suitability to address clinical data concerns, however, remains 
unanswered and further research is needed to test the application of Blockchain in real-world 
clinical trial environments.  Further research and studies are also necessary to address the many 













      









Information technology has rapidly been evolving in recent years to coincide with the increasing 
production and complexity of data. Data is being produced in such large quantities that new 
technologies must be developed that possess superior capabilities for the managing, analyzing, 
and storing of large complex data streams (Bashir, 2017). One area in which data is growing 
exponentially is clinical trials (Mackey et al., 2019). Clinical trials are intricate, time-consuming 
and expensive processes that produce immense quantities of complex and medically relevant data 
(Shamley and Wright, 2017). The World Health Organization (WHO) describe clinical trials as 
“a type of research that studies new tests and treatments and evaluates their effects on human 
health outcomes” (WHO, 2018). The number of clinical trials have been growing in recent years 
and consequently so too has the quantity and complexity of the data that they produce (Shamley 
and Wright, 2017).  
The Food and Drug Administration (FDA) and the Medicines and Healthcare products Regulatory 
Agency (MHRA) held a joint Good Clinical Practice (GCP) workshop in 2018 to discuss the 
increasing need for clinical data improvement processes due to the increasing numbers of trials, 
the increasing number of sites per trial, and the limited resources for oversight bodies in regulating 
and monitoring clinical trials across multiple locations (Khin et al., 2020). A concluding remark 
from these discussions were that “the importance of data integrity in clinical trials cannot be 
overstated” (Khin et al., 2020). Segen’s medical dictionary defines data integrity as “a dimension 
of data contributing to trustworthiness and pertaining to the systems and processes for data 
capture, correction, maintenance, transmission and retention” (Segen’s Medical Dictionary, 
2012). Additionally, the FDA issued a guidance document in 2016 titled “Data Integrity and 
Compliance” which defines data integrity as: “the completeness, consistency, and accuracy of 
data. Complete, consistent, and accurate data should be attributable, legible, contemporaneously 
recorded, original or a true copy, and accurate” (FDA, 2016). 
Data integrity is a fundamental requirement within CT research as all produced clinical data 
should represent a true and accurate reflection of the methods, outcomes and results of a trial, 
regardless of whether the data supports, disproves or challenges the trials original hypothesis 
(Friar and Kirsh, 2019). The clinical data functions to justify the efficacy and safety of a new 
medical intervention, treatment or drug, and is therefore critically important for the safety, health, 
and welfare of prospective patients (Shamley and Wright, 2017). How data is managed, stored 
and shared has been cited as being a recurring issue within clinical research and has been the 
subject of ongoing continuous improvement endeavors by regulatory authorities in recent years 
(Khin et al., 2020). Concerns of data transparency and integrity are cited to be key issues in 
clinical trials due to data inconsistencies, erroneous data, and data misconduct (George and Buyse, 
2015; George, 2016; Khin et al., 2020).  The Medical Research Council (MRC) defines research 
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data misconduct as the “fabrication, falsification, plagiarism, misrepresentation, mismanagement 
or inadequate preservation of data” (MRC, 2014). As the number of clinical trials and associated 
complexity and monetary investments grow, there may be a need to implement new data 
management systems that offer true data transparency, provenance and integrity (Hölbl et al., 
2018; Maslove et al., 2018).  
Blockchain technology (BCT) is a relatively nascent technology that was originally designed for 
the publicly perceived controversial cryptocurrency known as Bitcoin in 2008 (Nakamoto, 2009; 
Bashir, 2017).  Blockchains (BC) are decentralized public (or private) ledgers that utilize 
intelligent cryptographic hashing functions and sequential timestamping of transactional 
information to provide consecutively chained blocks of information in an append only, fully 
transparent, and tamper-proof ledger, that is spread across a peer-to-peer network (P2P) (Zheng 
et al., 2017). Following its original application with Bitcoin, Blockchains innate technological 
potential data solutions were quickly realized, and the technology rapidly began integrating into 
the finance industry. BCT has been cited as being a revolutionary and potentially “disruptive” 
technology (Mackey et al., 2019) and in recent years has begun diffusing beyond cryptocurrency 
and finance into sectors such as life sciences, healthcare, food and pharmaceutical supply chains 
and government. The life sciences and healthcare industries are where BCT can have a far-
reaching impact as these areas rely heavily on the transparency, traceability and trustworthiness 
of data shared amongst a network of stakeholders such as patients, healthcare providers, insurers, 
pharmaceutical companies and clinical researchers (Holdowsky, Lele and Lougheed, 2018). In 
2016 there were 5 PubMed publications with the word ‘Blockchain’ in the title or abstract as 
compared to 2018 when there were 64 publications. Healthcare data represented 32% of the total 
publications while clinical trials represented 4% (Mackey et al., 2019). There is a clear growing 
interest in this technology which is supported by its expected market growth. At present 
Blockchains market size is valued at $3 billion and is expected to grow to $39.7 billion by 2025 
(MarketsandMarkets, 2020). However, whether BC can be adapted for applicatory purposes 
within clinical trial data management remains to be seen, but there is a clear and evident interest 
in the proposition.  
BC has been proposed as a pragmatic solution for a myriad of data issues seen across industries 
and its potential benefits have begun to seep into the clinical research industry (Holdowsky, Lele 
and Lougheed, 2018; Hölbl et al., 2018; Mackey et al., 2019). Blockchain technology (BCT) 
offers advantages such as (Kuo, Kim and Ohno-Machado, 2017; Hölbl et al., 2018):  
• Fully transparent chronological and immutable data trails 
• No central intermediary to validate transactions 
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• Limits the possibility of a single-point-of-failure by being distributed across a multitude 
of nodes 
• Disincentives fraudulent activities through intelligent cryptographic functions 
• Auditability and traceability of all data  
• Increased security and accessibility of all data 
BCT offers a new way to manage and store data that could facilitate innovative methods for 
improving clinical data integrity (Benchoufi and Ravaud, 2017). There have been numerous 
discussions, pilots, and proof-of-concept (POC) studies to investigate the viability and efficacy 
of BCT in addressing some of the challenges associated with CT studies such as data integrity, 
recruitment and retention, management of informed consents, data provenance and data auditing 
for regulatory purposes (Benchoufi, Porcher and Ravaud, 2018; Maslove et al., 2018; Wong, 
Bhattacharya and Butte, 2019). BCT, while having existed since 2008, is still in its infancy of 
implementation within clinical research and industry (Mackey et al., 2019). There are many 
challenges that must be overcome, and it is inevitable that many more obstacles will present in 
the future. Besides technical challenges, there are social considerations to contemplate as is the 
case with any new technology, especially one that will effectively store and maintain sensitive 
data in an age where data forms the backbone of the digital society.  
 Research Purpose 
The focus of this research is to gain a deeper understanding of some of the key challenges 
associated with the integrity of clinical data and how an emerging technology such as Blockchain 
could address those concerns from a clinical data researcher’s perspective. BCT consists of a 
complex architectural infrastructure that is beyond the scope of this research, as is the actual 
technical application of the technology for clinical trials, however this is not the aim of the 
research. There are numerous ongoing and completed proof-of-concept studies that examine the 
technical applications of this technology with specific areas within clinical trials (Benchoufi, 
Porcher and Ravaud, 2018; Maslove et al., 2018; Wong, Bhattacharya and Butte, 2019). However, 
this research intends to examine the social awareness and attitudes to this technology and to 
subsequently attempt to determine if BCT could alleviate some of the data integrity issues 
encountered in clinical research from the perspective of those directly involved in clinical data 
management.  
In order to assess the suitability of Blockchain’s application in clinical research, study participants 
include those working within clinical trials who are involved in clinical data management such as 
Clinical Data Managers and Clinical Data Analysts who are key study participants as they are 
responsible for the management of data within a clinical trial and represent a key source of 
primary insight into the research topic. Literature is explored to determine the extent of the 
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concerns associated with clinical data integrity and study participants are interview through an 
online survey to determine if the literature correlates with their real-world experiences. Through 
a mix of qualitative and quantitative research, specific issues of data integrity will be investigated 
and theories of Blockchain technology applications are applied in order to determine the potential 
suitability of its application in improving data integrity.  
 Research Objective 
The research objectives of this study are as follows; 
• To gain a deeper understanding of the some of the key issues surrounding clinical 
research data integrity 
• To evaluate the current knowledge and awareness of Blockchain within the clinical 
research industry 
• To determine the suitability of Blockchain in addressing the key issues surrounding 
clinical data integrity from a clinical data management perspective through quantitative 
and qualitative research  
As there are no real-world examples of Blockchain being implemented within a clinical research 
setting at the time of conducting this research, the research here is primarily exploratory in nature, 
therefore no formal hypothesis can be formulated. With any new technology there are many 
unknown variable factors and often obstacles for implementation are unforeseen. 
 Justification for Study 
This research was undertaken due to the growing importance and relevance of data management 
in modern society and the associated issues relating with data integrity. This diffuses into clinical 
research data as the accuracy and dependability on the integrity of the data is instrumental for the 
successful outcome of the trial’s treatment; on which many prospective patients may depend 
upon. Additionally, Blockchain represents a truly potential solution for many of the data concerns 
seen in modern day data management across a range of industries. Its inherent advantages over 
current data management systems offer potential solutions that are worth exploring within clinical 
research. Blockchain is already being implemented and trialed across industries and areas such as 
the finance industry and the supply chain traceability within the food and pharmaceutical 
industries. With so much data being produced from clinical trials the coalescence of clinical data 
management with Blockchain seems like a truly beneficial endeavor to improve the integrity of 
clinical data. As Blockchain is slowly encroaching into the clinical research industry it is 
necessary to evaluate the perceptions and attitudes towards the technology as the technology will 
only prove to be effective if adopted by all stakeholders. It is the intent of this research to explore 
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those attitudes and also to outline the potential benefits Blockchain holds for the future of clinical 
data management. 
 Structure of the Study 
Chapter 1 introduces the dissertation and provide a brief background to the topic of clinical 
research integrity and a short introduction and explanation to Blockchain technology and clinical 
trials. The purpose of the research is outlined as well as the research objectives, justification and 
the structure of the dissertation. 
Chapter 2 consists of a literature review of clinical trial data management and some of the key 
issues surrounding integrity. Some of these issues include clinical data fraud and misconduct, and 
data traceability and transparency. An inclusion of how Blockchain works is included as this is a 
relatively new technology and will add context to the overall research. It is necessary to outline 
the functionalities and basic workings of Blockchain in order to examine its relevancy to clinical 
research data integrity such as traceability and transparency. Some of the key challenges with 
Blockchain and clinical trial research are discussed which include incompatibilities with data 
protection laws. Areas of clinical data integrity such as issues involving clinical data research 
misconduct and fraud as well as other clinical data concerns are highlighted from the literature 
which form the basis for the research methodology design. A conclusion of the literature is 
outlined along with gaps discovered and finally the conceptual framework is outlined.   
Chapter 3 outlines the research paradigm and the research strategy that the researcher used. A 
mixed methods approach was adopted aligning with a pragmatist research philosophy. The 
research overall is considered exploratory due to the nature of the infancy of the technology within 
the clinical research industry. An online survey consisting of quantitative and qualitative elements 
was issued to participants who were purposively chosen from a homogenous sample population. 
Participants were purposely selected who represent those with professions and backgrounds in 
clinical data management. Thematic analysis was applied to analyze the qualitative data produced 
while quantitatively produced data was analyzed in order to provide a complementary analysis 
with the qualitative data. Utilizing both methods allow for the breadth and depth of the responses 
to be further expanded.  
Chapter 4 evaluates and examines the results gained from the research applied methodologies 
and links to the research aims and overall topic. Thematic analysis is applied which highlights 
themes that arose from participants qualitative responses. These themes involve clinical data 
auditability, quality, transparency as well themes involving patients’ roles and vaccinations. 
Quantitatively produced data highlights some of the attitudes and perceptions to issues of clinical 
data integrity as well as Blockchain-related perceptions. The two sets of data are outlined in a 
complementary manner and function to support one another. Finally, a discussion of the findings 
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is included, and links are made to findings made from the literature review and correlations are 
highlighted between primary and secondary research data.  
Chapter 5 outlines the conclusion, limitations and recommendations of the study. Conclusions 
made from the research include how Blockchain has a strong suitability for addressing the clinical 
data concerns highlighted from the primary research, however there are numerous obstacles and 
challenges the technology must overcome and these are outlined here. Various limitations are 
identified and addressed such as the limited scope of the adopted research methodology. Finally, 
recommendations for further research are included and these consist of areas such as identifying 
and addressing the challenges that Blockchain must overcome before consideration of 









 Topic Outline 
This chapter outlines a review of the relevant literature and functions to support the study. The 
literature review attempts to gain a deeper understanding to some of the predominant data 
integrity issues that are associated with clinical trials. It also investigates why they may occur, 
while simultaneously exploring a new potential digital data management platform – Blockchain 
– and how this technology could address some of the main clinical data concerns that are 
discovered from the literature. The topics of research outlined in this section include an overview 
of BCT and how it works. This is necessary to understand its potential role within CT research 
and introduces the technology to the reader. Clinical data management is then explored in relation 
to clinical data misconduct and fraud. This links with the objective of gaining a deeper 
understanding to the issues that pertain to clinical data integrity. Following this a review of 
completed studies involving the application of BC within clinical research is explored. This ties 
in with the research objective of determining suitability of the technology for applicatory 
considerations. An overview of some of the challenges facing the technology such as GDPR are 
included and finally gaps within the research and the conceptual framework are included.   
Clinical data integrity has been cited by the FDA and MHRA to be a concern of importance in 
the last number of years (Khin et al., 2020), and has been identified as a historically and 
potentially ongoing issue (George and Buyse, 2015; Seife, 2015; Carlisle, 2017; Khin et al., 
2020). Issues that relate to data integrity include data transparency, traceability and accuracy. One 
area of concern relating to data integrity is data fraud. Data fraud is cited to be a rarely occurring 
phenomenon, however, George and Buyse, (2015) have suggested that clinical data fraud, while 
cited to be low, may in fact be much higher than is reported. This they argue can be due to a 
variety of reasons such as issues with definitional problems, problems surrounding study designs 
and under-reporting of fraudulent data in peer-reviewed papers. They consider the possibility that 
data fraud may in fact go undetected or unreported regularly (George and Buyse, 2015; George, 
2016). Seife (2015) identified multiple clinical trials in a study of 57 trials that exhibited instances 
of data fraud including data falsification and false information submissions to regulatory 
authorities. Seife also states that although evidence of data misconduct such as fabrication is 
identified, it is reported to rarely be reflected in peer-reviewed literature (Seife, 2015). Apart from 
intentional data misconduct, data integrity suffers as a result of the sheer volume and complexity 
of the produced data in clinical trials which leads to problems relating to transparency and 
ultimately integrity.  
Various studies and pilots have explored using BCT as a potential solution for improving issues 
of data integrity within clinical trials, but often lack any real observations or references to 
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instances of data fraud. Most of the studies which argue for improvements to data integrity 
utilizing BCT refer to the workings of George, (2016) and George and Buyse (2015) but often 
fail to explore beyond these studies. Furthermore, there is scarce literature examining the social 
perceptions and attitudes towards clinical data integrity concerns and BCT from an actual clinical 
data management perspective. In addition, much of the literature surrounding BCT proclaim that 
forcing stakeholders to use this technology would represent a challenge (Benchoufi and Ravaud, 
2017; Wong, Bhattacharya and Butte, 2019), but do not elaborate on how these findings were 
arrived at or how they could be resolved. Most of the proponents for BCT implementation seem 
to originate from technology-based backgrounds rather than clinical settings. Whether BCT 
represents a “hype cycle” that fails to deliver innovative promises but instead stagnates in the 
“idea” phase remains to be seen (Mackey et al., 2019).  
The literature explores some of the strategies that have been carried out for implementing BCT 
into clinical trials and addresses some of the gaps found within the literature. These gaps 
encompass areas such as sociotechnical barriers of implementation and the challenges associated 
and includes brief mentions of GDPR challenges. As Blockchain is a new and nascent technology, 
most of the literature surrounding its implementation and benefits is exploratory in nature.  
 Bitcoin – An Introduction to Blockchain 
In 2008, a person or persons under the assumed pseudonym Satoshi Nakamoto released a 
whitepaper: ‘Bitcoin: A Peer to Peer Electronic Cash System’. This paper outlined a “purely peer-
to-peer (P2P) version of electronic cash” that would facilitate online transactions between one 
party to another without the need for a third-party financial institution and “without relying on 
trust” (Nakamoto, 2009). Nakamoto identified several challenges and inherent weaknesses 
associated with third-party financial mediators, including the driving up of online transaction 
costs and fraudulent activities such as the double-spending problem (Nakamoto, 2009). In 
addition, central intermediaries represent a single-point-of-failure, meaning that if the 
intermediary was compromised the entire network could be at risk (Kuo, Kim and Ohno-
Machado, 2017). Bitcoin is a digital currency also known as a cryptocurrency that uses 
cryptographic proof to carry out digital transactions directly between transacting parties, instead 
of placing trust in a third party (Vujicic, Jagodic and Ranđić, 2018).  
Due to the anonymity of Bitcoin there was no way to verify and validate the transaction thereby 
preventing fraudulent activities. In order for Bitcoin to function as a decentralized public ledger 
without a central authority and to counteract the issue of fraudulent activities Satoshi Nakamoto 
conceptualized Blockchain, the technology which underpins the Bitcoin cryptocurrency platform 
(Vujicic, Jagodic and Ranđić, 2018). BC offers an alternative way of transferring data between 
parties without having to rely on a central mediator to validate the data transactions. The 
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anonymity of Bitcoin and Blockchain meant that the platform could be used to elicit illegal or 
nefarious online activities which has resulted in a negative perception of the platform by the public 
(Alshamsi and Andras, 2019).  
2.2.1 What is Blockchain? 
Blockchain is essentially a series of consecutively chained blocks which contain timestamped 
records of information that are maintained in a distributed public or private ledger across a 
network of computers also known as nodes. These nodes are linked together in a peer-to-peer 
(P2P) network; thereby negating the need for a trusted third party (Maslove et al., 2018). Each 
participating node in the network contains a local copy of the ledger meaning that if one node or 
more disconnects, becomes corrupt or fails for any reason, this has no effect on the overall 
network (Sarmah, 2018). This removes the vulnerability associated with central authorities that 
represent a single-point-of-failure, as the database exists on multiple nodes spread across a 
network which occurs in real-time (Zheng et al., 2017). This also means that if any local change 
is made to the BC it is replicated across the entire network resulting in each node updating their 
local ledger to match (Benchoufi and Ravaud, 2017; Vujicic, Jagodic and Ranđić, 2018). A 
Blockchain is considered immutable due to integrated cryptographic functions and the required 
validation of each transaction by each node (Sarmah, 2018). The differences between centralized 
and Blockchain networks are illustrated in figure 1.  
 
Figure 1: Centralized Network Vs Blockchain (Kuo, Kim and Ohno-Machado, 2017) 
2.2.2 How Does Blockchain Work? 
When a transaction is requested within a BC network it is uploaded to the P2P network of 
participating nodes. These nodes then validate the requested transaction and the user’s status using 
mathematical algorithms and by reaching a collaborative consensus (Bashir, 2017). A transaction 
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in the case of BC can be a digital financial transaction or can be a transaction of information. A 
consensus is reached by various different methods depending upon the Blockchain architecture 
used. For example, within the Bitcoin BC, a consensus is reached once 51% of the nodes agree 
and validate the new block (Lin and Liao, 2017). Once the transaction is accepted and validated 
it creates a new block and adds it to the growing chain of blocks (Zheng et al., 2017; Sarmah, 
2018). This process is illustrated in figure 2. 
 
Figure 2: How BC works (IPSpecialist, 2015) 
 
A block in a BC consists of data packages that contain a record of transactions or digital 
information. Each block is linked together by cryptographic hashes to form the chain of blocks 
(Hölbl et al., 2018). A block will hold all transactions that happened within that designated 
timeframe. When a piece of digital information or transaction is created on a BC network it is 
stored within a new block. When a new block is created the information will go through a hashing 
function which will calculate and assign a hash to that block. A hash is a mathematically 
calculated unique code assigned to each block; essentially a digital fingerprint. The hash is a 
function that will convert the digital information contained in the block; letters and numbers, into 
an encrypted digital output at a fixed length through a mathematical algorithm (Zheng et al., 
2018). The hash codes function to connect the blocks in a specific order with each hash being 
unique to each block (Mann et al., 2020). Each block is timestamped and also contains a reference 
(the hash) of the previous block in the chain (Hölbl et al., 2018). When a new block is added to 
the BC, each node within the network will work collaboratively to come to a consensus on the 
authenticity of the block (Zheng et al., 2017). Once a block is created it becomes a near immutable 
validated and encrypted set of digital information (Zheng et al., 2017; Sarmah, 2018). 
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There are various types of Blockchains, for example, a public BC such as Bitcoins BC allows 
anyone to join the network and represent as a node. Private and permissioned BC’s are managed 
and controlled by a single organization and require special permissions to join while consortium 
Blockchains are controlled by a group of organizations such as regulatory authorities, sponsors 
and contract research organizations. Private and consortium BC’s are only partially decentralized 
but still possess all the benefits such as timestamping and immutability as a public BC (Maslove 
et al., 2018; Mann et al., 2020).  
Figure 3 illustrates a typical example of a BC. Each block illustrated contains multiple 
transactional information’s denoted as TX1, TX2 and TXn, the hash of the previous block, a 
timestamp denoting the time of creation of the block and associated information, and a nonce 
which a randomly generated number used to verify the hash (Zheng et al., 2017).  
 
Figure 3: Typical example of a BC (Zheng et al., 2018) 
 
2.2.3 Blockchain: A Tamper-Proof Ledger 
Blockchain creates a tamper-proof ledger that is append only. If even a single character; letter or 
digit is tampered with in a block by a malicious user it will result in the change of the hash code 
of that block, meaning the subsequent hash of the following block would now be invalid. This is 
because the hash of the subsequent block in the chain is calculated using the hash of the previous 
block - which is now different. This results in a chain reaction of each block containing invalid 
hashes as each block would contain a hash that does not correspond with the hash of the previous 
block (Bashir, 2017; Zheng et al., 2017). If a malicious user wanted to change the information 
contained in an already validated block, they would need to re-calculate the hash of the block. By 
design, this requires significant computing power and if a person were to successfully re-calculate 
the hash of the block, they would then need to recalculate the hash of the subsequent. By altering 
the hash of the original block, every hash for every block in sequence would need to be re-
calculated, which is effectively impossible (Crosby, 2016).  
Any identical documents will produce an identical outputted hash, however, if even a single 
character in one of the documents is changed, it will result in an entirely newly outputted hash. 
This means that if a person received the document, they can compare its hash with the hashed 
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document within the BC. The document within the BC is immutable, therefore if the hash of the 
document they received matches the hash of the document on the BC, they know none of the 
information contained has been altered in any way and the integrity of the document is intact 
(Mann et al., 2020). The hash function in addition with the timestamp function ensures that 
information has not been interfered with and therefore provides a verifiable and tamper-proof 
historical record of all data transactions since the first genesis block (Wong, Bhattacharya and 
Butte, 2019). Due to its tamper-proof nature, BC can always ensure the integrity and sincerity of 
data by preventing data falsification after-the-fact (Benchoufi and Ravaud, 2017). This 
functionality of immutability has far reaching potential for the integrity of clinical data integrity 
which has historically been the subject of after-the-fact falsification and modification (George 
and Buyse, 2015; George, 2016).  
 Introduction to Clinical Trials 
Clinical trials are complex processes that represent a key research tool in the advancement of 
medical knowledge and the improvement of patient care. They are fundamental to the discovery 
of new treatments for diseases while also providing the possibility for new medical interventions 
for the detection, diagnosis, and reduction of diseases such as cancer as well as infectious and 
autoimmune diseases (Pocock, 2013). Clinical trials test the safety and efficacy of a certain 
treatment such as a drug or therapy throughout a number of defined phases (Phases I-IV) with a 
defined number of voluntary participants for each phase (Shamley and Wright, 2017).  They have 
a number of stakeholders who have a vested interest in the outcome of the trial, whether it is the 
sponsor who may invest large financial contributions in the hope of bringing a new potential drug 
or therapy to market or the patient themselves who may suffer from the condition the drug or 
therapy is designed to potentially treat (Shamley and Wright, 2017).  
The key stakeholders involved in a typical clinical trial consist of the clinical team, sponsor, 
IRB/IEC ethics committee, regulatory authority, study participants and sometimes a contract 
research organization (CRO). The study participant is arguably the most important stakeholder in 
a clinical trial and are voluntary eligible candidates who will sign an informed consent to 
participate in the study. The ethics board are responsible for ensuring that the trial remains ethical 
and in accordance with GCP guidelines while protecting the welfare and human rights of the 
participants. The sponsor may be a pharmaceutical company or institution that initiates and 
manages the clinical trial and may sometimes contract a CRO to manage or perform certain 
aspects of the study. The relevant regulatory authority is responsible for ensuring clinical trials 
meet quality, safety and efficacy requirements and overall are responsible for the approval of a 
new drug (Shamley and Wright, 2017). The Clinical Data Manager is responsible for the overall 
clinical data management process (Krishnankutty et al., 2012). All of these stakeholders must 
collaborate on a range of trial activities such as data management monitoring, regulatory 
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reporting, site monitoring, safety reporting and medical writing amongst others despite being 
geographically dispersed (Shamley and Wright, 2017; Triall, 2019). The various stakeholders are 
illustrated in figure 4 (Benchoufi and Ravaud, 2017). Clinical trials are separated into phases 
which represent separate trials with each phase intending to answer specific research questions. 
Each phase will have progressively more participants and time taken to completion. Phase III can 
involve thousands of participants over several years (Shamley and Wright, 2017).  
In 2010 there were 82,865 registered studies across the United States and in a further 213 
countries. In contrast, as of May 14, 2020, there are over 325,000 registered studies 
(ClinicalTrials.Gov, 2020). A study carried out by Wong, Siah and Lo (2019) found that almost 
14% of all drugs within clinical research trials eventually gain FDA approval but this still means 
86% of drugs fail to win market approval. They also found that non-oncology trials can run up to 
7.2 years while oncology trials can run up to 13.1 years (Wong, Siah and Lo, 2019). As the number 
of registered studies increases so too does the complexity of the trials, the number of participants 
and the monetary investments required by sponsors. A typical full clinical trial can cost in the 
range of $10 to $30 million and can go even higher in some cases, while the current estimated 
cost for bringing a new drug or therapy to market is between approximately $1 to $2 billion. It 
has been shown that cost of bringing a new drug to market rises by up 9% each year (Triall, 2019). 
Two of the primary cost drivers associated with clinical trials are data management and the 
ongoing requirement of compliancy with increasing regulations (Sertkaya et al., 2016).   
2.3.1 Data Management in Clinical Trials 
Clinical trials generate significant amounts of scientifically and medically relevant data regardless 
of the outcome of the trial, and therefore play an instrumental role in the advancement of medicine 
and patient care (Pocock, 2013). Clinical data is used by regulatory authorities for the approval 
decision making of new drugs and treatments while additional stakeholders such as research 
institutions, medical devices, pharmaceutical companies and prospective patients alike all rely on 
clinical data being accurate, transparent and traceable (Maslove et al., 2018). Regulatory 
authorities rely on the reproducibility of clinical data in order to reconstruct the trial to confirm 
the integrity of the data (Khin et al., 2020). However, accuracy, transparency, traceability and 
reproducibility of clinical data has historically been a fundamental and recurring issue within 
clinical research as approximately 80% of clinical trials are cited as being non-reproducible 
(George, 2016; Benchoufi and Ravaud, 2017; Khin et al., 2020). The non-reproducibility of trials 
is due to a variety of data-related problems such as erroneous data, data fraud and misconduct and 
data misrepresentation (Benchoufi and Ravaud, 2017; Wong, Bhattacharya and Butte, 2019)  As 
the complexity of data increases alongside with the number of active trials, it is evidently 
becoming increasingly important to secure the accuracy, transparency and traceability of all 
clinical data that is produced throughout a study.  
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A typical clinical trial consists of numerous concurrently running data streams that are intertwined 
to produce complex and substantial quantities of data that require constant monitoring and 
analysis by multiple involved clinical staff. This includes data involving recruitment and 
retention, consent forms, data monitoring and analysis, security reporting and protocol 
management (Benchoufi and Ravaud, 2017). Figure 4 illustrates an overview of the various data 
streams and involved stakeholders associated with a typical clinical trial. When managing large 
amounts of clinical data that is subject to change it is essential to ensure that there is an audit trail 
that is immutable and historically accurate, however, this currently represents a major issue for 
regulatory authorities within clinical trials (Hume et al., 2017; Khin et al., 2020).  
 
Figure 4: Overview of clinical trial data streams and relevant stakeholders (Benchoufi and 
Ravaud, 2017) 
 
2.3.2 Clinical Data Integrity Concerns 
Maintaining clinical data integrity is intrinsically important in clinical research as erroneous data 
could result in a new drug being rejected for market approval by the relevant regulatory oversight 
bodies. It could also result in additional studies being carried out and can result in adverse  
reputations for pharmaceutical companies (Khin et al., 2020). Inconsistent, unreliable and 
inaccurate data can incur monetary cost implications for sponsors and may result in aspects of the 
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trial requiring repeating thereby increasing the length of the trial (Gupta, 2013). Trust in the 
integrity of clinical data is vitally important not just for the outcome of a trial, but also for post-
trial completion and subsequent regulatory approval of a treatment and subsequent post release to 
market. A considerable amount of sensitive data must be monitored and validated while shared 
and should be made accessible in a reproducible and transparent manner. In addition, it must be 
guaranteed that data remains private and inviolable (Albanese et al., 2020).  The International 
Council for the Harmonization of Technical Requirements for Pharmaceuticals for Human Use - 
Good Clinical Practice (ICH-GCP) offer guidelines on how clinical trials data should be managed, 
monitored and carried out and state that “All clinical trial information should be recorded, 
handled, and stored in a way that allows its accurate reporting, interpretation and verification” 
(ICH, 2018). Despite GCP guidelines, clinical research has been the subject of numerous issues 
surrounding how data is managed, stored and shared (Seife, 2015; George, 2016; Benchoufi and 
Ravaud, 2017). As clinical trials become larger and more complex, they produce larger volumes 
of data that require labor-intensive management on an on-going basis, and this subjects the data 
to the possibility of data errors, whether unintentional or malicious (Wong, Bhattacharya and 
Butte, 2019). Data errors and inconsistencies can be the result of honest erroneous data entries or 
can be the result of data misconduct such as fabrication and falsification (George and Buyse, 
2015; George, 2016).  
2.3.3 Clinical Research Data Fraud and Misconduct 
Clinical research data fraud and misconduct is not an unheard-of phenomenon within clinical 
research. George (2016) suggests that researchers may commit data fraud or data misconduct for 
personal and/or financial gain or can be the result of the mounting pressure placed on researchers 
to meet trial objectives under increasing regulatory requirements and financial constraints 
(George, 2016). Researchers as well as sponsors have strong incentives to publish positive data 
results which can have a damaging effect on public health if the data is unreliable and erroneous 
(Scarso Borioli and Couturier, 2018). A study carried out by Seife in 2015, found that out of fifty-
seven published clinical trials included in the study that were subjects of  FDA inspections, 22 
trials were found to have a falsification or submission of false results, while 42 trials were found 
to have inadequate or inaccurate data recordkeeping (Seife, 2015). Seife reviewed several 
published inspection documents by the FDA and identified “major violations of GCP, including 
allegations of fabrication and other forms of misconduct” (Seife, 2015). Additionally, according 
to Seife, departures from GCP are often not disclosed by the FDA and findings are rarely cited or 
reflected in peer-reviewed journals even if evidence exists to support misconduct or erroneous 
data.  
George (2015) illustrates several high publicity cases in which research investigators committed 
clinical data fraud. One high publicity case included a researcher who was found to have 
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committed data fraud in 172 research papers which included 126 papers that contained fabricated 
reporting of results (George and Buyse, 2015; Carlisle, 2017). The literature is replete with 
historical high profile cases of clinical data misconduct and fraud (Gupta, 2013; George and 
Buyse, 2015; Seife, 2015; George, 2016). Furthermore, Carlisle (2017) identified possible data 
misconduct in 90 trials when reviewing data from 5,087 published clinical trials by incorporating 
statistical tools to identify data inconsistencies. He noted that the statistical data patterns recorded 
in the 90 trials were highly unlikely to occur by chance and indicated nefarious instances of data 
manipulation and fabrication (Carlisle, 2017). It is clear from the literature that data misconduct 
is not an uncommon occurrence and the likelihood of incidences may in fact be higher than 
expected or reported.  
However, despite these findings, actual prevalent proof of data misconduct is in fact cited to be 
low as the true rate of occurrences can be problematic to estimate. This is supported by George 
(2016) who describes some of the possible reasons behind this. For example, determining 
prevalence and proof of misconduct can be challenging as it can be difficult to clarify who the 
study population is when investigating misconduct. Numerous surveys and investigations have 
attempted to determine prevalence in recent years resulting in disparate and conflicting 
conclusions (George and Buyse, 2015). The data produced from the study carried out by Seife 
(2015) was not quantitative but descriptive. This was due to the limitation of the procured data 
coming from what was publicly made available by the FDA, which was often redacted, and which 
also was updated infrequently on the FDA website (Seife, 2015). Clinical research data 
misconduct can vary in severity and if the regulatory authority such as the FDA discovered 
evidence of a violation, it does not mean that it is required to be publicized or included in an 
article and often FDA documents are redacted making it difficult to determine which trials were 
found to have data misconduct (Seife, 2015). It must also be considered that anomalies of data 
found within literature could in fact be attributed by misinterpretation or simple human input data 
errors, or honest transcription mistakes. Nevertheless, it may difficult to prove widespread 
prevalence, but its occurrence is fact. 
Although it may be difficult to measure and quantify the extent of actual clinical data misconduct, 
the probability of it occurring within a high-pressure environment is not outside the realm of 
possibility. It can be surmised that possible minor data instances of misconduct may go undetected 
on a regular basis. In addition, clinical data misconduct may not always be the result of an 
intentional action, but rather the result of ineffective and poor management (Gupta, 2013). Poor 
data management systems or high-pressure environments could result in carelessness of data 
entries by clinical staff.  Proof of data misconduct in clinical trials may be low, but honest data 
errors, honest mistakes, and poor data management is reported to be a widespread issue (George 
and Buyse, 2015; Benchoufi and Ravaud, 2017). Improving data integrity is an ongoing endeavor 
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as regulatory bodies such as the FDA, WHO, the European Medicines Agency (EMA) and the 
MHRA who have all released guidance documents pertaining to the necessity for the 
improvement of clinical data integrity in the last number of years (Khin et al., 2020). Regardless 
of the original intent of data misconduct, whether malicious or accidental, clinical data integrity 
is ripe for an effective, transparent and immutable data audit trail overhaul. Erroneous data results 
in financial and reputational damage which can impede clinical trials objectives and any attempt 
to improve its integrity should be explored.   
 Blockchain-Enabled Clinical Trials 
Due to Blockchains immutability, it can in theory greatly reduce the possibility of data misconduct 
occurring as any data inputs can be traced back to the origin and the data cannot be altered once 
uploaded due to the cryptographic hashing functions.  Real-time data access in a BC-enabled 
clinical trial will allow relevant stakeholders to monitor data continuously and this in theory 
would have significant impacts of the quality of produced data. With current clinical data 
management systems, it is becoming increasingly difficult to trace data back to its origin or to see 
who has also accessed it or modified it a point in time. This is due to data being stored across 
multiple locations and in a centralized manner. With clinical data stored on a BC, data provenance 
is greatly enhanced as data can be traced back to its origin with full transparency and trust. It has 
however, been suggested that Blockchain is facing an innovation plateau caught in a ‘hype-cycle’ 
as is the case with many new technologies (Mackey et al., 2019). However, BC has a proven track 
record in terms of its applicability with cryptocurrency trading which by design is ‘trust-less’. 
One can be absolutely assured that data on the BC is 100% transparent and accurate and if this 
proven track record can seep into clinical data management it could potentially overhaul how all 
clinical data is stored and shared going forwards.  
2.4.1 Ensuring Data Integrity through Blockchain Regulatory Auditing  
Regulatory authorities such as the FDA are responsible for ensuring that clinical trial 
methodologies are conforming and adhering to GCP guidelines and facilitate this by auditing on-
site records and data (Hirano et al., 2020). A lack of transparency and traceability of data increases 
the likelihood of erroneous data going undetected and the FDA stated traceability and 
transparency to be among their top predominant data issues that need to be addressed (Hume et 
al., 2017). Sponsors must be able to prove data provenance and integrity and be able to address 
queries from oversight bodies in order to maintain integrity of data throughout the trial. This is a 
time consuming, expensive and difficult process for both the sponsor and the regulatory authority 
(Mackey et al., 2019). Audit trails provide the regulator with the necessary data to ensure the 
trials data integrity. Khin et al., (2020) whom reviewed the discussions between the FDA and 
MHRA outline that audit trails are critically important for capturing data collected from a study 
and should clearly outline who added data, when it was added and what was added. Furthermore, 
20 
 
appended data should not obscure the original data and data should not be deleted once entered. 
They also observe that audit trails should be accessed and reviewed throughout the study in an 
easily accessible manner by the regulator to ensure ongoing data integrity (Khin et al., 2020). 
Blockchain possesses the architecture that can facilitate this and can transparently provide full 
data provenance from origin to completion to concerned regulatory authorities on a real-time 
basis. BC could enhance the trust in data allowing regulators to streamline the approval process. 
The traditional practice in clinical research for ensuring data integrity and accuracy has been 
100% source data verification (SDV). SDV is when data collected in a case report form (CRF) or 
other data collection systems are compared with the original source of data or information to 
confirm the accuracy of the transcription of the information. SDV has been estimated to cost up 
to 25% of the clinical trials entire budget. However, as clinical trials grow in size and complexity 
it is becoming increasingly difficult to apply 100% SDV. One of the reasons for this is the 
increasing regulatory requirements imposed on clinical research (Hirano et al., 2020). Regulatory 
bodies such as the FDA released a paper suggesting the use of alternative methods to 100% SDV 
with an emphasis on the consideration of electronic monitoring approaches (FDA, 2013). Wong, 
Bhattacharya and Butte, (2019) recognized the need for increased clinical data integrity and 
correlated this with the need for a real-time auditing methodology for regulators. They modelled 
a private BC based on a simulated prototype phase II clinical trial which incorporated real data 
from a previously completed trial. Control of their BC was given to the regulator (hypothetically) 
who in theory would carry out real-time auditing of data from the data uploaded to the BC. All 
data created since the genesis block would be available in an immutable and chronological manner 
and with BC’s function of cryptographic hashing the integrity of the BC’s data can always be 
maintained. All additions to the append only BC can be traced back to the author via digital 
signatures and hashing. This enables true transparency and traceability of data (Hume et al., 
2017). There are several limitations to this proof-of-concept study. For example, forcing all 
stakeholders or participating parties can be a challenge due to sociotechnical barriers. Only data 
recorded on the BC could be considered for regulatory purposes, this would not include any 
offline transactions and entering data on a BC does not eliminate data fabrication or falsification 
at the point of origin (Wong, Bhattacharya and Butte, 2019).  
Maslove et al., (2018) have also suggested the use of a private BC to streamline regulatory 
auditing with their POC called BlockTrial. Some of the limitations outlined in the study also 
included sociotechnical barriers for stakeholders in adopting a BC enabled clinical trial data 
infrastructure. Hirano et al., (2020) also identified data integrity as being a key issue and 
examined the impact of incorporating BC to enable real-time auditing by oversight bodies. From 
these studies it is evident that BC could streamline and even accelerate the drug approval process 
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while providing regulators with transparent data that they can query in real-time which could 
disincentivize data misconduct or even careless data erroneous inputs.   
2.4.2 GDPR & Blockchain Tensions 
As with any nascent technology, challenges are numerous concerning its adoption and 
implementation. One predominant issue facing BCT is the European General Data Protection 
Regulation (GDPR). GDPR is based upon the assumption that there is a ‘data controller’ for each 
personal data point. This contradicts BC’s platform in that there is no single ‘data controller’ but 
instead there exists multiple controllers. This raises the concern of ownership and accountability 
of clinical data stored on a BC (European Parliament, 2020). This may be bypassed in CT research 
if the BC was private and permissioned and central control was given to one stakeholder such as 
the sponsor (Wong, Bhattacharya and Butte, 2019). A second concern is that data can be modified 
or erased under GDPR regulations in order to comply with any legal requirements (European 
Parliament, 2020). However, BC is built upon its immutability an append only architecture 
thereby modification or erasure of data is not possible (Zheng et al., 2017). Data contained on a 
blockchain is usually encrypted or hashed (particularly in permission-less BC’s) and there is still 
ongoing debate as to whether encrypted data qualifies as personal data. The tensions between BC 
and GDPR are extensive and intricate, particularly when personal health is concerned. In addition, 
there exists not one ‘Blockchain’ but many types with varying and disparate features and 
architecture (European Parliament, 2020). Therefore, it may be the case that there is only one 
standardized BC that is simultaneously designed to handle all areas of CT research from consent 
to data sharing while also remaining compliant with data protection laws. However, studies in the 
area of CT data remain underdeveloped and it may transpire that there may be a need for several 
BC’s to handle each individual area of CT research rather than one single BC. In conclusion it is 
evident that there is much research to be carried out regarding BC and data protection laws and 
at present this will most likely represent a key challenge.  
 Key Findings  
Below is a list of the key findings discovered from the literature: 
• There multiple clinical data issues identified from the literature. These involve data 
issues relating to traceability, transparency, quality and auditability which all contribute 
towards the general integrity of clinical data 
• There have been multiple recorded incidences of data fraud and data misconduct 
contributing towards the lack of general trust in the validity and reliability of clinical 
trial data 
• There is a regulatory recognition that clinical data integrity is an ongoing concern that 
needs to be addressed  
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• Blockchain has been considered for the application of all areas of data management 
within clinical research from consent approval and management to recruitment of 
potential candidates to the management and traceability of clinical data throughout the 
trial and post completion of the trial 
• There may be negative perceptions to the technology from the public which may 
weaken its brand and may act as an obstacle for its successful integration within clinical 
data management 
• There are currently no clinical trials that have implemented the technology indicating 
the technology is still in its infancy of consideration for implementation and there are 
most likely significant challenges that must be overcome, however, these are seldom 
mentioned throughout the literature 
• Blockchain is complex and intricate and this may act as a inhibitory factor for its uptake 
by clinical staff   
• Due to the emerging and nascent nature of this technology, it can be presumed that there 
is a lack of BC experts who are also proficient in regulatory clinical data compliancy 
laws  
• BC is potentially caught in a ‘hype-cycle’ and may never come to fruition  
 Gaps in the Research 
There are extensive gaps in the literature pertaining to the challenges that face BC’s 
implementation with clinical data management. Although it is not the intention of this study to 
examine the challenges facing BCT, these will be explored lightly in the primary research, as 
this could form the basis for future work and represents a key area which should be explored. 
There also exists gaps in the literature concerning the uptake of this technology amongst 
professionals within the clinical research industry. It may surface that stakeholders are simply 
not comfortable using a technology that has a negative association with something like Bitcoin, 
or they may simply not trust the “trust-less” technology for the management of personal health 
data. This general mistrust may come down to a lack of understanding of how the technology 
works and this will form the basis of the research.  
 Conclusion of Literature 
It is clear from the extensive studies and literature that BC holds far reaching potential benefits 
for the traceability, auditability, integrity, security and transparency of clinical data. Various POC 
studies have proposed BC for almost all aspects of clinical research, however one area that is 
scarcely examined is the attitudes and social technical adoption of BCT. There may exist social 
barriers to its adoption as many researchers may not even be aware of this potential “disruptive” 
technology. Most of the literature which professes the potential benefits of BCT for the 
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improvement of clinical research data integrity refer back to the studies carried out by George 
(2016) and George and Buyse (2015), however, often seldom explore beyond these studies. There 
is no literature or research that is inclusive of actual clinical data managers or opinions of clinical 
data and integrity and this presents a gap that should be explored.  
While it is clear there is a market for BCT in clinical trials, there still exist no real-world 
applications within clinical studies at the time of this research and no research to evaluate the 
attitudes and receptiveness of the technology by the clinical research industry. The application of 
BCT may be frivolous if its uptake and implementation is rejected by researchers and stakeholders 
alike. In addition, data integrity encapsulates a wide range of sub-topics ranging from data fraud 
to honest data errors and poor data management and BCT may not be the solution for these issues. 
Deeper real-world investigations are required to determine and examine the attitudes and 
perception of this technology in the effort to improve clinical data integrity. Blockchains 
association with cryptocurrency may potentially yield an unfavorable reputation as untrustworthy, 
as cryptocurrencies are often deemed intrinsic in eliciting illegal online transactions where users 
remain anonymous (Bashir, 2017). BC is considered “trustless” due to its cryptographic hashing 
functions, but ironically the social perception of trust for the technology may remain an obstacle 
for its implementation. There may be a distinct lack of understanding of the true potential of BC 
and its potential for enhancing and streamlining the management of clinical data.  
It is important to note that the aim of this study is not to identify or prove instances of possible 
research misconduct or to analyze the possible potential repercussions and consequences of it, but 
rather to highlight the possibility of occurrences, and to investigate how a technology such as BC 
could be implemented to potentially prevent the possibility of it occurring in the future. It is also 
not the intention of this study to highlight possible investigational inconsistencies by regulatory 
authorities into clinical misconduct, but instead to outline a new and untested method of data 
auditability that could be implemented to improve data integrity and real-time auditing. 
Pharmaceutical companies are faced with an increasingly difficult regulatory landscape in which 
to deliver trials designed around patient safety in accordance with GCP guidelines (Khin et al., 
2020). There is pressure from sponsors to recruit and enroll target study participants as well as to 
successfully reach trial objectives and timelines and all within budgetary allocations. There is 
pressure from research ethics committees for trials to align with ethical and moral standards and 
even pressure from patients who are placing their personal dependencies upon the successful 
outcome of a trial (Shamley and Wright, 2017). With such a high number of variables it is 
reasonable to surmise that there exists various cases of questionable research practices and 
misconduct as well as a range of honest mistakes. However, improvements in clinical data 
management represents a key area in which many solutions for data errors, intentional or 
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malicious, could be derived from and Blockchain could potentially be the solution for some of 
these issues.   
 Conceptual Framework 
One of the key findings from the literature is the lack of research into the social attitudes of clinical 
researchers to BCT and clinical data integrity. This will form the fundamental basis for the 
research undertaken. BCT proponents profess the benefits that BC holds for the challenges 
associated with clinical research data integrity, yet there exist no real-world applications at 
present. Authors of BC advocacy in alleviating data integrity in clinical trials tend to loosely base 
their frameworks and ideologies on the studies carried out by George (2016) and George and 
Buyse, (2015) but fail to explore whether BCT can provide the solution for the proposed ongoing 
problematic data integrity trends. To date, from the examined literature, there has been no 
qualitative and quantitative research from directly involved clinical staff such as Clinical Data 














 Topic Outline  
The objectives of this research are to gain a deeper understanding to some of the predominant 
issues surrounding clinical data integrity, to evaluate the current knowledge, awareness and 
perceptions of BC by clinical data staff, and to explore the suitability of BC in addressing the 
issues pertaining to clinical data integrity. Through a mixed method approach the study aimed to 
explore first-hand from clinical data research staff what they believe some of the primary 
concerns are that are associated with data integrity and how they feel they could be improved. 
This ties in with the research objectives of firstly examining the perceived issues relating to 
clinical data integrity. Perceptions and awareness of BCT will be evaluated and following this, 
the application of BCT will be explored in relation to clinical data integrity.  
This chapter outlines the chosen research philosophy, strategy, purpose, process and research 
logic. Also included are the research methodology, sources of data, the sampling methods, 
analysis of data, and an outline of any access and ethical issues. A pragmatist inductive approach 
was taken with this study of which the research purpose was considered exploratory. The research 
method used was a complementary quantitative and qualitative mixed methods approach. The 
sources of data consisted of an online survey while the sampling methods employed were non-
probability and purposive homogenous sampling. A thematic analysis approach was then taken 
in order to analyze the data produced from the qualitative questions and the quantitative data was 
analyzed in conjunction with the qualitative data.  
 Research Philosophy 
The term research philosophy refers to a system of beliefs and assumptions about the development 
of knowledge and relates to how a researcher’s intrinsic perceptions and beliefs influence their 
interpretations and understandings about the nature of the world. This ideology of beliefs and 
assumptions play a role in the way in which researchers gather, analyze, and use data, as a 
researcher strives to develop knowledge in the particular field in which they are studying 
(Saunders, Lewis and Thornhill, 2015). Throughout research, the researcher formulates a series 
of types of assumptions either consciously or subconsciously (Burrell and Morgan, 1979). These 
include: 
• Ontological assumptions about the nature of reality 
• Epistemological assumptions about human knowledge 
• Axiological assumptions about human value and ethics 
The assumptions made by the researcher will overall effect and shape the researchers 
understandings of the research questions, methods used, and the subsequent interpretation of the 
findings (Saunders, Lewis and Thornhill, 2015). Affecting these assumptions is a continua which 
are two extremes known as objectivism and subjectivism. Objectivism argues that social reality 
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is external to us and that social entities exist independently within one general reality. In 
objectivism the researcher is typically detached from the research and employs quantitative 
research methods, implying that facts and figures garner the best scientific evidence. Employing 
subjectivism means a researcher is typically attached to the research carrying out qualitative 
research (Saunders, Lewis and Thornhill, 2015). Subjectivism argues that social reality is 
formulated from the perception and consequence of people and that there are multiple perceived 
and experienced realities. Subjectivism involves the researcher to be more inclined to be 
interested in the various opinions and narratives to account for different social realities (Saunders, 
Lewis and Thornhill, 2015). Taking a subjective approach allows the researcher to be 
introspective of their own values and while they cannot detach from their values, they can 
incorporate them into their research. The subjective researcher will ultimately endeavor to 
understand the differing realities in order to make sense of the situation and to instill a sense of 
meaning rather than empirical evidence such as that of the objective researcher (Saunders, Lewis 
and Thornhill, 2015).  
There are four major types of research philosophies (Saunders, Lewis and Thornhill, 2015). 
• Positivism can be described as taking the natural scientist philosophical that entails 
working with a social reality that is observable producing law-like generalizations. 
Positivists focus more on collecting empirical evidence and facts rather than socially 
attributed meanings and impressions. Positivists will generally lead a quantitative study 
to test an existent hypothesis or develop one with existent theory in objective manner. 
• Realism relates to scientific enquiry and describes the truth of reality being what our 
senses show us. Realism refers to objects existing in reality independently of the mind’s 
perceptions and beliefs, in other words, their conceptual scheme. There are two subtypes 
of realism; direct and critical realism.  
• Interpretivism can be described as a form of positivism but with a subjective perspective 
and advocates the necessity to understand the differences between different social actors 
and emphasizing the way in which each human creates and experiences different social 
realities. Humans act out their roles according to the meaning they attribute to these roles. 
Interpretivism researchers will adopt qualitative methods.   
• Pragmatism researchers reconcile objectivism and subjectivism and often combine both 
positivism and interpretivism within the scope of their research. A pragmatist philosophy 
argues that the research question is the most important determinant of the research 
philosophy and will use whatever methods and philosophies necessary to further their 
research. They believe there are multiple ways to interpret reality, that multiple realities 
may exist and that multiple methods may be used when undertaking research, and that 
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that there is no single philosophy or set of ideologies that can best describe the entire 
picture.  
For the purpose of this research a pragmatist research philosophy was chosen as the research 
paradigm underpinned by epistemological assumptions. The dichotomy presented between 
subjectivism and objectivism is not recognized by the pragmatist researcher, instead the 
researcher seeks to reconciliate the two contrasting concepts (Saunders, Lewis and Thornhill, 
2015). A pragmatist approaches aligns particularly well with the mixed methods approach 
adopted as part of this research as the pragmatist researcher uses whatever means necessary to 
garner the necessary information and data that best facilitates the research question. Each 
participant within the study will have their own set of ideas and beliefs pertaining to the issue of 
concern and each may have alternative practical methods or solutions to address these issues. This 
approach allowed the researcher to become immersed in the perspective, interpretation and 
experiences of the clinical research staff which aid the researcher in further developing their 
knowledge of the issues and concerns without being confined by the contentious ideologies of 
truth and reality. Epistemologically, participants have their own experiences and knowledge that 
govern their responses to questions pertaining to clinical data integrity and BC. A pragmatist 
approach allowed for the collection of these experience and knowledge-based answers to form 
the basis for the pragmatic need for adopting BC to meet the data integrity issues outlined.  
3.2.1 Research Design  
The overall research approach for this dissertation was considered exploratory. This approach was 
adopted in order to gain a deeper insight into clinical data integrity from experts working directly 
within the industry – an area which has been seldom explored in relation to BCT. The exploratory 
research approach includes a search and review of the literature pertaining to clinical data integrity 
issues and BCT’s potential applicability and relevance within clinical trials. This was followed 
by carrying out an online survey with clinical staff directly involved in clinical data management 
such as Clinical Data Managers to gain a deeper insight and perspective. Exploratory studies are 
useful in clarifying an understanding of a phenomenon or problem (Saunders, Lewis and 
Thornhill, 2015). In this case, the application of BCT in addressing clinical data integrity concerns 
from clinical staff will most likely not provide conclusive evidence that this technology can 
actually improve data integrity. But it was important to explore the necessity of introducing an 
entirely new data management system when managing and storing such sensitive clinical data. 
The insights gained from clinical staff will be useful for future considerations of implementing 
this technology in a real-world case. In addition, the social acceptances and perceptions of 
introducing new technologies such as BCT within clinical workplaces to handle data will also be 
beneficial for future related studies. A personal investigation is adopted which consists of an 
online survey that uses both quantitative and qualitative style questioning. 
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3.2.2 Research Process and Research Logic 
There are two main ways in which data can be collected, these are qualitative and quantitative. 
Quantitative methods are often aligned with the positivism paradigm. Quantitative methods are 
often employed to directly examine relationships between variables utilizing standardized 
empirical and statistical recording methods of data. Qualitative methods are often aligned with 
the interpretive paradigm as researchers employ these methods to gain a deeper understanding 
and clarity of the subjective and socially constructed meanings regarding the issue or phenomenon 
being studied (Saunders, Lewis and Thornhill, 2015). Qualitative data collection methods are non-
standardized, unlike quantitative methods. In addition, research may be inductive, deductive or 
abductive. Inductive research is associated with developing theories as a consequence of the 
analysis of the discovered data and aims at gaining insights into the meanings attached to 
situations or events. Induction research is often aligned with the interpretivist paradigm. 
Deductive research involves the development of theories and hypotheses and subsequently testing 
them by collecting appropriate data to confirm or disprove the hypothesis (Saunders, Lewis and 
Thornhill, 2015).  
For the purpose of this research a mixed methods inductive research process was adopted by using 
an online survey. By employing a mixed methods approach, the pragmatist researcher can add a 
level of complexity and depth to their research by incorporating both quantitative and qualitative 
mixed methods (Saunders, Lewis and Thornhill, 2015). A qualitative approach was selected in 
order to gain a deeper insight into the proposed issues of clinical data integrity. This approach 
unearths some of the primary concerns relating to data integrity and highlights some of the 
attitudes and perceptions of clinical staff in adopting BCT to address some of these concerns. Due 
to the limited participants involved in the study, the qualitative approach is supported by a 
simultaneous complementary quantitative approach. The reasoning for this choice was to 
preemptively tackle the issue in which a participant had limited or no prior knowledge of BCT. 
For this reason, some of the questions were multiple-choice, hence a quantitative approach. This 
allowed the participant to choose an option they deemed to be the most satisfactory answer based 
on their own professional experience and knowledge while albeit possibly possessing limited 
knowledge of BCT. Quantitative and deductive research are often associated together within 
research (Saunders, Lewis and Thornhill, 2015). However, although quantitative questions were 
incorporated into the survey, the researcher did not consider these questions to be deductive as 
they functioned to support and complement the qualitative data. It was not the intention of the 
research to implicitly lay out empirical data that represented a target population, but to inductively 
apply both quantitative and qualitative questioning styles to complement the responses from both 
data sets to support the discoveries from the literature.  
30 
 
The multiple-choice options were derived from discoveries that were found within the literature 
review and form the most relevant subject areas of applicability. Each multiple-choice question 
had an ‘other’ option. If the participant felt that none of the provided options best correlated with 
the question and their own personal experiences, they could then add their own personal response 
under the ‘other’ option. This strengthened the mixed method approach while both facilitating 
those who have experience and prior knowledge of Blockchain with those who do not. 
Furthermore, limitations of incorporating quantitative questions in an online survey setting were 
recognised, especially in the case of participants having a lack of prior knowledge of BC as this 
could lead to uninformed responses which could affect the reliability of the survey.  Part of this 
research was to determine awareness of this technology and participants were chosen who were 
most likely to be have been aware of BCT based upon their professional background. However, 
during the research process where a participant has not heard of BCT to any extent, a brief 
unbiased explanation of BCT was provided to participants. The ideal scenario was to interview 
participants with extensive knowledge and insight into both BCT and clinical data integrity, 
however from secondary research it was foreseen that this may not be the case as BC is still such 
a new technology and relevant participants were not readily available at the time of the research 
to engage in the study. Therefore, based on these findings, the survey questions were designed 
with both quantitative and qualitative methods in mind so both approaches could support and 
overcome any weaknesses that may be found by using just one approach.   
Due to the inductive and exploratory approach no theories or hypotheses were applied at the start 
of the research. Using an inductive approach will allow a researcher to identify emerging themes 
throughout progression of the research by recognizing socially contextual meaning and 
understanding the perceptions study participants have relating to the research questions and 
objectives (Saunders, Lewis and Thornhill, 2015). Taking this approach can prove problematic as 
inductive research can often take significant time to uncover and identify trends on which to build 
upon, however, based on the researchers understanding of the study, this was the most appropriate 
approach to take in order to analyze the data. Although surveys are often associated with a 




 Sources of Data 
The collection of data was gained from an online issued survey with clinical data research staff 
members directly involved in clinical data management and data inputting. The survey was 
designed to evaluate how clinical data suffers from issues of integrity and the main causative 
factors that contribute to integrity problems. Surveys can be useful mixed methods approach of 
gaining qualitative and quantitative data as they can encompass both open-ended and closed 
questions (Saunders, Lewis and Thornhill, 2015). Due to the limited number of respondents, this 
survey approach cannot be said to be reflective of the population of interest, however, this is not 
the intention as the questions were designed to be inductive by nature. Open-ended questions 
allow participants to share their own personal answers based on their own perceptions, 
experiences and personal knowledge (Saunders, Lewis and Thornhill, 2015). This lends towards 
the exploratory nature of this research. Quantitative questions included in the survey were 
designed to be complementary with the qualitative questions and vice-versa. The survey was 
shared with those for whom the research was aimed towards namely those currently or have been 
in the past involved with clinical data management.  
As there are no real-world applications of BCT in use in a clinical trial setting identified at the 
time of this research, questions regarding BCT include a brief introduction to the key points and 
potential applications of the technology. Awareness of the technology may be low, and this was 
accounted for when designing questions relating to its functionality and implementation. 
Furthermore, while on the surface, proponents of BCT profess that BCT holds enormous 
‘obvious’ benefits for clinical trial data integrity, this may not be the real-world case. While the 
researcher is slightly biased in favor of this; based on the findings from the literature review, the 
questions regarding BCT are structured as best as possible as not to appear to be biased in favor 
of its implementation. Questions regarding BCT predominantly seek to outline the attitudes and 
awareness of its potential application and this links with overall research objectives of 
determining the perception of the technology in relation to CT data integrity concerns.  
 Sampling Methods 
This was a mixed methods exploratory research with no sample frame and a non-probability 
sampling technique was used as the sampling method. Homogenous purposive sampling was used 
to select cases that would best represent those who could meet the research objectives. The 
researcher’s judgment was used to purposively select participants using clear criteria of those of 
whose profession involved clinical data management and analysis as these participants best 
represented the sample population who could provide meaningful data regarding both clinical 
data integrity and data relating to BC. Potential participants were selected based upon their 
professions by searching on social media platforms such as LinkedIn and Facebook. In addition, 
online groups such as Clinical Data Management groups were identified and from there further 
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participants were purposively selected to be included upon acceptance of participation. 
Homogenous sampling was employed by using a small pool of study participants and this meant 
that statistical interferences were not used to answer the research objectives and while 
generalizations could still be made from non-probability sampling regarding the research 
questions, they were not based on statistical grounds (Saunders, Lewis and Thornhill, 2015). 
Although there were elements of quantitative research incorporated as part of the survey 
processes, they functioned to support the qualitative research and do not statistically represent the 
general population. Participants were geographically dispersed, with most participants being 
based in Ireland and one participant being based in the United Kingdom.  
BCT was predicted to be generally unheard of in the clinical research industry, and so the 
probability of most clinical research staff being aware of the technology was to be expectantly 
low. Those involved directly with clinical data management were the most likely candidates to 
have a pre-existing knowledge of BCT due to the nature of their profession and therefore represent 
the best-fit participants to meet the study objectives. The researcher used personal judgment based 
upon findings in the literature review and from real-world knowledge to come to the conclusion 
that those involved with clinical data management would be the most suitable candidates of 
having some prior knowledge of BC as BC would have a somewhat strong reputation in 
technological data-based professional backgrounds. Therefore, homogenous sampling was 
selected based upon these judgments. Selecting participants such as clinical nurses for example, 
would not represent a suitable sample selection as they would most likely have less in-depth 
knowledge regarding clinical data integrity and BC as those directly involved with clinical data 
management. Incorporating homogenous sampling does mean that the likelihood of the sample 
being representative is low and this represents a limitation of the study. Saunders, Lewis and 
Thornhill (2015) suggest a sampling size of between 4-12 when the nature of the study consists 
of a homogenous population. Given the time constraints of the study the sampling size was kept 
to a minimum of 9.  
 Reliability and Validity 
Reliability incurs that a study is consistently reproducible (Saunders, Lewis and Thornhill, 
2015). There are many possible issues concerning reliability when carrying out a mixed survey 
approach methodology. Participants can be affected by a range of factors which may interfere 
with their willingness or their assiduity when engaging with research studies such as surveys. 
Participants may rush through the questions as they may have undertaken the survey during a 
time-sensitive period of their day, and this may reflect a disparity in answers then if the 
participant undertook the survey when they had more time to complete it (Saunders, Lewis and 
Thornhill, 2015). While this may not necessarily be the case for quantitative aspects of the 
survey, it may be the case for qualitative aspects. To enhance the reliability the sampling size 
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could be increased, however, due to time limitations, the sampling size was kept low. Despite 
extenuating factors that may affect participants, survey questions were designed to produce 
reproducible results thereby incurring reliability with the intended study population. Reliability 
issues arise when using self-completed surveys as data collection methods as they can 
sometimes result in uninformed responses. This may occur due to the participant possessing a 
lack of knowledge or experience to effectively answer the questions, which can result in 
guesswork. However, participants are more unlikely in a self-completed survey to answer 
questions to please the researcher or as a result of social pressures as can happen with interview 
processes which can lead to increased reliability (Saunders, Lewis and Thornhill, 2015). 
Questions were designed to be as unambiguous as possible such that the respondent dissected 
and answered the question as was intended meaning the answers could be understood and 
interpreted effectively.  
Validity which refers to the way in which the measures used as part of the research actually 
work to answer the research questions (Saunders, Lewis and Thornhill, 2015). Questions 
utilized as part of this research were designed to in the best way possible to ensure that their 
importance measured up to the research objectives. Both quantitative and qualitative questions 
within the survey have either a direct, or leading link towards answering the research questions 
overall.  
3.5.1 Pilot Testing Survey and Alterations 
While originally intended as a purely qualitative survey designed to be carried out in an 
interview setting, extensive alterations were made to various questions while converting some 
questions to quantitative multiple-choice questions. This change in data collection strategy was 
deemed necessary following the lack of respondents willing to participate in a purely qualitative 
interview-based survey. Upon altering the data collection strategy to include both qualitative 
and quantitative methods, participants were much more willing to complete the survey. Prior to 
sending the online survey for data collection, it was pilot tested with a past MSc student. 
Following this, minor alterations were made to some questions to improve clarity and the 
sequences of questions was altered to improve the logical flow of the questioning.  
 Analysis of Data 
As the online survey consisted of a mixed method approach, data produced was both 
quantitative and qualitative which was designed to be complementary. These two methods were 
designed to support each and the two sets of data were analyzed in conjunction with each other. 
Thematic analysis was utilized to analyze the qualitative responses from participants. This 
approach is useful for identifying and analyzing themes that arise within data (Saunders, Lewis 
and Thornhill, 2015). In this case a theme represents an important element within the data that 
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relates to the overall research objectives. A theme is subject to the researcher’s perception and 
does not necessarily depend upon prevalence of occurrence. Additionally, a theme is not 
necessarily required to be quantifiable, but can depend upon the researcher’s deemed 
importance in relation to the research objectives. As themes emerge, they are coded. In the case 
of this research inductive coding was used which coincides with exploratory nature of the 
research. Inductive coding is useful when there conducting research when there is limited 
knowledge of the topic (Braun and Clarke, 2006). Thematic analysis was applied to the 
qualitative data and analyzed together with the quantitative data in order to support one another.   
 Access and Ethical Issues 
As this research includes a literature review of data fraud and misconduct, ethical considerations 
are paramount to deliberate for the research process. Research questions were designed to infringe 
as little as possible into morally ambiguous lines of enquiries. Study participants were not 
questioned in such a way that would implicate themselves, their organization or any other 
person/organization in an unfavorable or questionable manner. Furthermore, there will be no 
reference made to any persons/organizations/companies. The rights of all participants should be 
recognized, and their dignity respected while the researcher must practice integrity and avoid 
misrepresenting the data and findings and avoid deception and dishonesty. Furthermore, the 
privacy of the participants was guaranteed including their anonymity, while their right to 
withdraw for any reason was respected and not challenged in any way (Saunders, Lewis and 
Thornhill, 2015). Each participant was briefed on the overall objective of the research and the 
questions that would be included and was informed that all data collected would remain 
anonymous and no personal information would be included or shared under any circumstances. 
The invitation text sent to participants for the online survey can be found under appendix 1. As 
this was an online survey, informed consent was built into the survey. An outline of the informed 
consent can be found under appendix 2. As the methodology was originally designed to consist 

















 Topic Outline 
This primary objectives of this research were to highlight and explore the key areas that affected 
data integrity in clinical trial research. Following this, the technology Blockchain was explored 
through secondary research to examine its potential appropriateness and suitability for use within 
clinical trial research, particularly in addressing some of the key concerns of clinical data 
integrity. Through secondary research it was deemed that BC such was a relatively nascent and 
emerging technology within clinical research that it was necessary to evaluate the awareness and 
perceptions of this “trust-less” technology within clinical trial data management and how it could 
potentially impact upon the integrity of clinical data. An online survey method approach was used 
to collect primary data and incorporated both quantitative and qualitative questioning styles. The 
answers received through the survey provided an insight into clinical data issues that participants 
felt required improvements and their shared perception and understanding of BCT was 
discovered. The presented data in this section follows the flow and sequence of the questions as 
they were presented in the survey to participants. 
Participants were first asked a descriptive question about their current/past roles within clinical 
data management to assess the relevancy and validity of their responses. The question put to 
participants was “Are you currently involved with clinical trials and could you briefly explain 
your role within clinical trial data management”? Of the responses, one was not involved in any 
way with clinical trials but had some knowledge of clinical data management systems but worked 
in an IT background with a strong knowledge of BC and so was included in the results. Other 
roles included: Clinical Data Analysts, Clinical Data Managers, Clinical Data Coordinators, 
Clinical Data Leads and a Clinical Trial Manager of global studies who had strong interests in 
BC and Artificial Intelligence technologies. One further participant was involved in systems 
validations projects for clinical trial management computer systems. While these roles vary 
slightly, they were considered to be non-probability and homogenous.  
 Clinical Data Integrity Issues 
The first half of the survey aimed to establish the awareness among participants in relation to 
clinical data integrity concerns, and to gain a deeper understanding to some of the primary 
issues that contribute to the integrity of the data directly from participants.  
4.2.1 Clinical Data Awareness 
From secondary research it was suggested that issues surrounding clinical data integrity were 
potentially under-recorded and under-reported. It was therefore important to first gain an insight 
from participants into whether they were aware that there have been ongoing issues concerning 
clinical data integrity before asking participants to expand deeper into the issues. This was 
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presented to participants quantitatively as “Are you aware that there have been ongoing concerns 
relating to the integrity of clinical research data?”, the results of which are outlined in figure 5. 
 
Figure 5: Pie chart representing the responses from participants when asked if they were aware of 
ongoing concerns with clinical data integrity 
 
All respondents claimed that they were aware of ongoing concerns. One participant added that 
they were aware of data inconsistencies possibly due to fraud. This is particularly interesting as 
data misconduct and data fraud were not presented within the questioning in the survey, but as 
found in the literature, fraud and misconduct are cited to be an occurring phenomenon. The results 
from this section were important in order to establish the validity and relevance of the research. 
The responses indicate the broad awareness from the participants involved with clinical data 
management that there are in fact clinical data issues that are ongoing that may need addressing 
and highlight the need for possible data management solutions.  
To expand upon this, participants were asked the qualitative question “In your opinion, is clinical 
data integrity an important aspect of clinical research? Please provide reasoning for your answer”. 
Participants elaborated on their understanding of clinical data integrity by pointing out that results 
gained from trials should be accurate, trusted and non-biased. Trust in data was the over-arching 
theme that surfaced among participants with respondents elaborating that data should be trusted 
to be consistent ensuring the validity of the trial’s outcome and its reproducibility. Trial 
reproducibility was a factor that surfaced within the literature and depends on the data being 
traceable, consistent and reliable. This question highlighted the understanding participants had 
surrounding clinical data integrity based upon their professional experience and knowledge. 
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4.2.2 Prominent Clinical Data Concerns 
Participants were asked the quantitative question “What would you consider to be the most 
prominent clinical data concerns from the following?”, the results of which are outlined in figure 
6.  
 
Figure 6: Bar chart representing responses participants made when asked to choose two 
predominant areas of data concerns 
 
The optional choices for this question were gathered from discoveries within the literature that 
made up the primary general areas in which clinical data was cited to be an issue. Data 
transparency and data quality represented the majority of votes, followed by real-time 
accessibility, traceability and auditability. Data quality surfaced as a recurring theme throughout 
the qualitative thematic analysis as being a fundamental factor of consideration for improvement. 
One of the noted limitations of figure 6 was the inclusion of data quality as this could arguably 
be an umbrella term to include areas such as transparency and traceability. Also, to gain a more 
meaningful data set it may have been necessary to widen the number of participants. However, 
the intent of this question was to complement the qualitative responses gained from participants. 
It may have been more effective to exclude data quality and to ask participants to choose only one 
option. However, the disparate choices made by participants correlate with the findings from the 
secondary research as all options were chosen at least once by participants. This indicates there 
are multiple perceived issues that contribute to the overall integrity of clinical data.  
Following this a qualitative question was asked which was “If you are aware of any clinical data 
areas that could be improved upon, could you outline them below and give a brief description as 
to why you chose them?”.  Responses were quite varied but supported the quantitative data gained 
outlined in figure 6. One participant pointed out that there are frequent changes in clinical teams 
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which can lead to increased loss of trial knowledge, however, did not elaborate further leading to 
a degree of ambiguity in the interpretation of the answer. However, another participant also 
contributed, that due to a lack of clinical personnel understanding, maintaining different sources 
of data could prove quite challenging. They pointed out how maintaining various sources and 
matching within clinical databases could prove quite difficult when personnel do not understand 
the requirements. A further participant also mentioned how securing sources of data can be 
problematic and that there can be incompatibilities between paper and digital records. Two 
separate participants mentioned the need for trust in clinical data within vaccination data 
management with one participant mentioning the possibility of a central repository for which all 
vaccination clinical data originated from for which the data the integrity of the data could be 
guaranteed. This presents a very applicable use for BC as BC is designed to be a single source of 
all data that by design ensures both privacy of data and integrity through its immutability design 
functionalities.   
4.2.3 Real-Time Accessibility to Clinical Data 
It was difficult to ascertain the level in which clinical data staff had access to real-time clinical 
data from secondary research. To gain an insight into this, participants were asked “In your place 
of work is there real-time access to all clinical data as it becomes available?”, the results of which 
are outlined in figure 7. 
 
Figure 7: Pie chart representing responses when participants were asked if they had real-time 
accessibility to all clinical data 
 
Six of the respondents claimed they did not have real-time access. An “other” option was included 
in which one respondent stated that they had partial real-time access to certain data such as data 
from electronic Case Report Forms (eCRF) but did not have real-time access to central laboratory 
or electrocardiograph results. One respondent stated they did have real-time access but did not 
elaborate further and one respondent chose irrelevant as they work in IT. One of the key 
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characteristics of BCT is its architectural ability to showcase data in full-time allowing all relevant 
parties access to data as it appears and so it was interesting to find that even in today’s data 
management systems, real-time accessibility to all clinical data is often not available. This creates 
a strong case for the implementation of BC with clinical data management.  
Following this a qualitative question was asked which was “In your opinion, would clinical trials 
benefit from real-time access to data as it becomes available? Please provide an explanation for 
your answer”. All respondents emphasised the benefit from having access to clinical data in real-
time. Two participants pointed out how sponsors would benefit from this as they often require 
data in time manners but as one participant pointed out that the collation of the data takes before 
it can be sent. Participants also pointed out how following up issues would be made substantially 
easier with real-time access with two participants pointing out how better decisions regarding data 
could be made more efficiently resulting in the easing of the trials progression while enhancing 
the quality of the data. Two participants also mentioned the potential of real-time access for 
vaccination trials with one participant mentioning the increased trust a patient would be provided 
with if they knew the integrity of the data was assured. While another participant mentioned the 
possibility of improved delivery times of vaccinations if real-time access was implemented. While 
real-time accessibility of data was not stated to be among the top two primary concerns as seen 
in figure 6, it can still be considered an important aspect that could improve the integrity of clinical 
data. Having real-time access to data allows erroneous and inconsistent data to be identified at the 
time of origin rather than down the line. 
4.2.4 Legacy Clinical Data Management Robustness 
Participants were “How robust, in your opinion are current Clinical Data Management systems in 
ensuring clinical data is accurate, traceable and intact?”, the results of which are outlined in figure 
8. 
 
Figure 8: Pie chart representing the responses participants made when asked how robust Clinical 




Participants were asked this question to gain an idea of how effective they perceived their current 
data management systems to be in contributing towards clinical data integrity. Responses greatly 
varied with 5 of the respondents stating that current clinical data management systems were 
moderately robust while 2 of the respondents claimed they were not robust. This question was 
critically lacking in relevance and failed to allow for a deeper analysis into current clinical data 
management systems. Although this question lacked relevancy and depth it did however show the 
rather disparate opinions participants shared in relation to their current data management systems.  
 Blockchain and Clinical Data Management 
Following establishment of the primary clinical data concerns from respondents, they were then 
asked questions pertaining to BC. These questions established the awareness, understanding and 
perceptions of the technology as well as highlight the obstacles and challenges facing its 
implementation.  
4.3.1 Blockchain Awareness 
Part of this research was to determine the level of awareness among participants and so 
participants were asked the question “Prior to this study, were you aware of the technology 
called Blockchain?”, the results for which are outlined in figure 9. 
 
Figure 9: Pie chart representing the responses from participants when asked about prior 
knowledge of BC 
Participants answers relating to subsequent BCT questions were dependent upon their prior 
knowledge and awareness of the technology, so it was positive to find that more than half were 
aware of BC prior to starting the survey. It was found that 6 participants possessed prior awareness 
while 3 stated they were not aware prior to the commencement of the survey. Participants were 
purposively chosen who best represented the professions in which they would most likely have 
heard of BCT. As BC is currently being implemented across a range of industries for purposes 
such as data management and traceability, it was assumed that those working in clinical data 
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management would have some prior knowledge of the technology based upon their professional 
backgrounds. However, the value was expected to be lower and it was a concern that if the overall 
level of awareness was lower that it would impact or possibly invalidate the remaining responses 
regarding BC and its role within clinical research. Of those who stated they were not previously 
aware of BCT involved those involved with clinical data coordination, clinical data management 
and data governance and a participant whose profession was clinical data lead. It is interesting to 
note that in the introduction of chapter 1, it was found that in 2018, out of 64 PubMed publications 
with the word ‘Blockchain’ in the title, only 4% were represented by the area of clinical trials. 
While it was found that interest with BC within clinical research was accelerating, awareness 
within the industry was still relatively low, and while the results of this study are not intended to 
be empirically representative of a population, it is interesting however to note that participants 
such as those involved with clinical data coordination and clinical data management and 
governance, had not previously heard of this technology. This does possibly highlight the level in 
which BC is still in its incipient stages of application within the industry.   
4.3.2 Blockchain Understanding 
Participants were also asked “How would you describe your understanding of Blockchain?”, the 
results for which are outlined in figure 10. 
 
 
Figure 10: Pie-chart representing the responses participants made when asked to rate their 
understanding of BC 
 
Responses greatly varied, however it was interesting to find that 3 respondents claimed to have a 
strong understanding of BCT, while 3 claimed to have an idea of what the technology was. This 
quantitative response does not correspond with when participants were asked if they had prior 
knowledge of BC before commencing the survey. Previously, 3 participants had mentioned that 
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they had no prior knowledge of the technology which does not coincide with the previous results 
where only 1 of the respondents stated it was the first time they had heard of BC. This does suggest 
a degree of unreliability with the survey and it is possible questions were not presented as clear 
and concise as they could have been. It is also possible there was not enough differentiation 
created between these two questions regarding awareness and understanding of BCT. Gaining an 
insight into participants awareness and understanding of BCT as well as their awareness of 
clinical data integrity concerns was important to identify themes that surfaced when qualitatively 
asking participants further questions. It was to be expected that there would be a degree of a lack 
of prior knowledge of BC but those participants who had not heard of BC were still able to add 
meaningful data relating to clinical data integrity issues. As participants were chosen who best 
represent the population that would most likely have pre-existing knowledge of the technology 
based upon their professional backgrounds, it can be surmised that the awareness and knowledge 
extending beyond clinical data management within the clinical research industry is most likely to 
be lower.   
4.3.3 Impact of Blockchain on Clinical Data Integrity 
Participants were then asked the qualitative question “Given your prior knowledge of (or from 
the introduction provided) of Blockchain, how do you feel clinical data integrity could be 
impacted by this technology?”. This provided an opportunity for participants give their insight 
and opinions into how BC could benefit clinical data management. Responses were quite mixed 
with one respondent simply stating that it could improve traceability, transparency and integrity 
while a second respondent claimed it could improve the quality, integrity and reliability of clinical 
data. One participant pointed out that there exists a degree of traceability by audit trails with 
datapoints integrated in current management systems but that BC they believed would enhance 
that that traceability. Another participant mentioned how BC would improve the audit trail for 
any data entered into the study. Another respondent pointed out the benefit BC provides 
regulatory authorities and future researchers as having all data on a BC would aid in the 
reproducibility of the trial.  
4.3.4 Challenges Facing Blockchain 
Participants were asked the question “In your opinion what do you think could be the primary 
challenges in adopting this technology within clinical trial research?”. Participants were asked to 




Figure 11: Bar chart representing choices participants made when asked to choose two options 
that would likely present as challenges when considering BC adoption within clinical research 
 
The responses were as follows: Forcing all stakeholders to use the technology - 2. Issues and 
incompatibilities with data protection laws such as GDPR – 2. Lack of awareness and 
understanding of the technology - 3. Complexity of the technology - 5. Regulatory compliancy - 
1. While it was not part of the research objectives to examine the challenges associated with BC 
and clinical research, it was appropriate in determining the suitability of its implementation. 
Complexity of BC scored was rated the highest and considering the responses from participants, 
this was not particularly surprising. Following this was a lack of awareness and understanding of 
the technology. It is interesting to note that complexity of the technology was the highest rated 
challenge associated with BC adoption. Despite this being rated as the highest challenge, the 
majority of respondents claimed they would be inclined to use BC over current legacy data 
management systems. However, even so participants have recognised that BC is still a complex 
technology. One participant pointed out that there needs to be BC experts who are proficient in 
areas of BC and clinical trial data management. As it stands, this is an area that is lacking as BC 
is an inherently complex piece of software architecture. An interesting avenue to explore would 
be the user-friendliness of its user interface in managing clinical data. This would however be a 
test limited to actual testing of the technology within a clinical trial management environment. It 
was not surprising that complexity and also lack of awareness and understanding of BC rated the 
highest obstacle. Participants within the survey most likely would not have prior knowledge or 
experience when concerned with for example the incompatibilities of BC with data protection 
laws or issues with regulatory compliancy. It seems likely that the lack of understanding and 
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complexity need to be addressed before participants can assert valuable responses in relation to 
other areas of challenges. 
Following this, participants were asked to the qualitative question “In your opinion do you think 
stakeholders such as regulatory authorities and clinical researchers would benefit from sharing 
and storing clinical data on a Blockchain? Provide reasoning for your answer”. All responses were 
favourable towards the benefit stakeholders would gain from using BC. One participant pointed 
out humanity have produced more data in the last 10 years than the entire history of our species 
previous to that. They further mentioned how the production of data is increasing exponentially 
every day. It can only be assumed that as we progress into the future, we will continue to increase 
the production of our clinical data continuously. It is therefore reasonable to suggest that there 
should be suitable way to manage that data to ensure its complete traceability and integrity. For 
clinical research, at this point in time BC appears in theory to be able to provide that. Participants 
mentioned how clinical researchers would have access to data contained in a BC to further their 
studies while resting assured that all data is immutable and can be proven to have not been 
tampered with in any way.  
4.3.5 Reputation and Perceptions of Blockchain 
Participants were asked a qualitative question which was “Blockchain is typically associated with 
Cryptocurrencies such as Bitcoin and negatively perceived online activities. How do you feel this 
would impact upon the perceptions and adoption of this technology within clinical research”? BC 
is a platform that was built and originally intended for Bitcoin. As was seen in the literature review 
the perceptions of Bitcoin are rather ambivalent and therefore it was prudent to gain an insight 
into participants perceptions and attitudes to BC. The central idea of this research revolves around 
data integrity and trust. BC by design is a “trust-less” technology meaning the need for trust is 
designed to be omitted from its functionality. However, the pharmaceutical industry is particularly 
conservative as mentioned by one participant and when personal data such as clinical data is 
considered there may be a degree of distrust placed in a new data management platform. The same 
participant pointed out that the conservativeness of the clinical research industry can be based 
upon the uncertainties of whether a drug is safe and effective yet and therefore adopting BC will 
require extensive understanding from different stakeholders. Two participants mentioned how 
they think of cryptocurrencies when hearing BC which could weaken its brand and present 
uncertainties in that people may be suspicious of sharing their personal details with BC. Another 
participant added that cryptocurrency transactions within BC are trusted even though they take 
place in an un-trusting environment. They mentioned that this professes proof of its applicatory 
purposes. It is ironic that that there are trust issues associated with using the technology, despite 
the technology being designed to be trust-free. Responses to the perceptions were mixed, while 
some mentioned that people will be suspicious of sharing personal data which is out of their 
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control which was consolidated by a further response mentioning security issues with protecting 
patient data while a further added that dissociating BC from Bitcoin may prove difficult. From 
the responses gathered it is evident there is a degree of mistrust and uncertainty of the technology, 
however this may come down to a lack of understanding as 3 participants claimed to have little 
to no understanding of the technology. Adoption of new technologies can only really be 
considered if they are accepted and understood by those who will be using them.  
4.3.6 Is BC ‘Over-Hyped’? 
Participants were asked the question “It has been suggested that Blockchain is an ‘over-hyped 
technology. Given your knowledge, how would you respond to this statement?”, the results of 
which are outlined in figure 12. 
 
Figure 12: Pie-chart representing the choices participants made when asked to rate their response 
to the statement of BC being an ‘over-hyped’ technology 
 
It had been suggested from secondary research that BC was facing a stagnation of innovation 
plateau, in that it was facing the issue in which many new technologies face – being ‘over-hyped’. 
Participants were asked this as it ties in with the research objective of examining the perceptions 
of the technology. Surprisingly responses fell between 5 respondents choosing they somewhat 
disagree and 3 choosing they strongly disagree. Again, there are disproportionate inconsistencies 
in the data here as participants who stated previously that they had no prior knowledge of BCT 
should have been more inclined to choose the undecided option. This can incur several things; 
some participants made an uninformed choice, or the survey was biased towards the positive 
characteristics of BC introduced by the style of questioning. This questions the validity of the 
questions and again questions the reliability of the survey. Although certain elements of data may 
be skewed, 3 of the participants chose to strongly disagree with BC being an ‘over-hyped’ 
technology. This indicates that perceptions among participants is in favour of the technology, but 
it is difficult to ascertain a true value due to the inconsistencies of data from certain participants. 
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It should also be noted that one participant possibly chose not to answer this question as they 
previously stated they had no prior knowledge of BC. 
Finally, participants were asked “Would you personally be inclined to use this technology over 
current legacy data management systems?”, the results of which can be seen in figure 13. 
 
Figure 13: Pie chart representing responses from participants when asked if they would be 
inclined to use BC over current data management systems 
 
The majority of respondents claimed they would be inclined to use BC over current legacy data 
management systems which is particularly interesting given the varied responses to previous 
questions such how well respondents understood the technology. In figure 10, 3 respondents 
claimed to have a strong understanding of the technology while 3 claimed to have an idea of 
what it was while the remaining stated, they did not know anything about BC. It should be noted 
that one respondent chose not to answer this question. One respondent chose to mention the 
obstacles facing BC but did not indicate if their inclination towards adopting the technology. It 
is interesting to note that while a degree of uncertainty persisted in participant responses, most 
stated they would be inclined to use BC which is promising.  
 Themes Identified  
Thematic analysis was applied to identify the common recurring themes that surfaced from 
qualitative responses. Some of the primary themes are outlined below. 
4.4.1 The Patients Role 
A theme that surfaced within the research was the role of the patient and how they could benefit 
from a BC-enabled clinical trial. The patient’s role was something that was gathered from carrying 
out secondary research and although patients were not included in the survey, responses indicated 
that patients are more involved with their personal health and health-related data. One respondent 
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suggested that data contained on a BC that is immutable and encrypted would enhance the level 
of trust patients have in sharing and entrusting their data with clinical researchers. The patient is 
particularly important to consider as they are arguably the most important stakeholders within 
clinical trials. Patients who participate in clinical trials are often relying on the success of the trial 
to treat their specific medical needs and it is necessary that they trust that their data is secure, safe 
and traceable. 
4.4.2 Trust in Clinical Data 
Trust in data is a theme that popped up quite frequently throughout the survey responses. Almost 
all respondents in some form mentioned trust in data. One participant stated that the data collected 
in a clinical trial should be exactly as it was, that it has not been tampered with and there should 
be a degree of confidence that it has not been altered in any way especially when it forms the 
basis for clinical research. Another respondent also added that clinical trials are responsible for 
producing high quality data and it is critically important that the data remains unaltered and stored 
in a secure environment.  This was a fundamental theme that also surfaced when carrying out 
secondary research as it was found that data fraud and misconduct had occurred throughout trials 
in the past affecting the trust placed in the data. Trust is an overarching factor when considering 
any kind of data, especially clinical data. Fundamentally there must be trust that the data is 
accurate and truly representative of the trials results, without trust, reliability and reproducibility 
of a trials methodologies and results are called into question. The patient must be able to trust 
their data is in safe hands, the regulators must be able to trust that the data is accurate, transparent 
and auditable. These are all elements built into BC technology. Although BC cannot prevent 
erroneous data at the point of origin, in other words it cannot prevent someone inputting wrong 
data, it can however provide a trail of time-stamped connected data from the point of origin right 
throughout the entire data production process. Data cannot be altered or changed in the append-
only ledger, thereby incurring trust in that the data has not been modified or altered at any point.  
4.4.3 Trial Sharing of Data 
A theme that cropped up was the sharing of clinical data between ongoing trials. This particular 
area was not researched as part of the study. However, as one respondent mentioned having a 
central repository of depersonalised clinical data would be shared within the clinical research 
industry would be particularly beneficial. While the idea of this is attractive, there may be 
numerous complications of achieving a central repository of clinical data such as the ownership 
of data. Another respondent stressed the need to keep all personal clinical data from appearing 
within data management systems. The respondent mentioned this as an area that required 
improvement and that personal data should never appear in data systems. This ties in with the 
need to create trust in the storage and sharing of personal clinical data as mentioned previously. 
The respondent went on to mention how there is a huge amount of data circulating the world 
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today and that more data has been created in the last 10 years than the entire history of the human 
species. This is a particularly interesting point to take into consideration to take into account when 
considering the implementation of BCT. BCT, according to the research has the architectural 
capabilities to store exponential amounts of data in a distributed shared ledger, while maintaining 
the data in an encrypted and immutable format. 
4.4.4 Vaccination Trials 
The theme of vaccinations surfaced from responses. Some participants pointed out the need for 
integrity in clinical data, especially in relation to vaccination data. The theme of vaccinations is 
a particularly interesting area to examine in relation to BC. Participants noted that how the 
compilation of vaccination data across various trials could be stored in a central repository such 
as BC and that real value in data could be harnessed by combining artificial intelligence pattern 
recognition software with the data produced from numerous trials. This is an attractive concept, 
however, the practicalities of this would face enormous obstacles. The question of ownership of 
and accessibility of the data would be called into question. In theory, having all clinical data 
from all clinical trials across multiple pharmaceutical companies stored and shared in a single 
master BC would be enormously beneficial to the advancement of medicine, however, is an 
unrealistic expectation. From the responses it can be indicated that there is a degree of mistrust 
in vaccination clinical data and this is potentially consolidated due to the Covid-19 pandemic 
that is currently ongoing at the time of this study. One participant mentioned how BC could be 
used to improve the trust from a patient perspective for vaccination trials while another 
participant mentioned how delivery times would be increased.  
 Discussion 
When considering clinical data integrity, it necessary to consider how data transparency, 
traceability, real-time accessibility, auditability and data quality all contribute to the overall 
integrity of clinical data. These areas were all identified as concerns among participants through 
both quantitative and qualitative questioning and these correlated with the findings from the 
secondary research. Themes that were discovered included how trust could be enhanced for 
patients, the role of real-time data accessibility within vaccine trials, how BC could improve the 
integrity of clinical data by preventing tempering and alteration of data once uploaded. The 
general consensus gained from participants indicated a favourable perception towards BC 
however, it was clear from participants that there exist various of challenges to overcome. 
Complexity of the technology and a lack of awareness of the technology represented the highest 
quantitative responses from participants as challenges. As Bitcoin and consequently Blockchain 
may have unfavorable public reputations, this may act as a challenge for the uptake of the 
technology in traditionally conservative industries such as the pharmaceutical industry. Lack of 
public trust in a designed to be “trustless” technology may ironically act as a prohibitory factor in 
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its widespread adoption within clinical research, however this remains to be seen. Responses to 
questions were quite varied and a degree of inconsistency was noted throughout the survey 
responses.  There are clearly many potential uses for a technology such as BC. Its application for 
real-time sharing of vaccination trial data is a particularly interesting area of potential future 
research as two participants seemed confident in the need to improve vaccine data trust and 
delivery times of vaccines.  
The first research objective of this research was:  
• To gain a deeper understanding of the some of the key issues surrounding clinical 
research data integrity 
Primary data gained from this study presented the areas of concern that were to be expected as 
proposed by the secondary research. However, limitations of the scope of questions and the lack 
of follow up investigation prevented a thorough in-depth analysis into these specific areas. While 
the key issues were identified, their root causes why they occur were not identified. Participants 
did not elaborate much beyond the specific issues that had been identified. However, some 
participants did point out incompatibilities and issues between digital and paper records which is 
an area that could be further explored in future research.  
The second research objective was: 
• To evaluate the current knowledge and awareness of Blockchain within the clinical 
research industry 
The primary data gained from this research pertaining to this objective was mixed. There were 
inconsistencies in responses throughout the survey, so it was difficult to ascertain a true 
representative idea of the awareness and knowledge of BC among participants. It was however, 
predicted that the majority of participants would have no prior knowledge, but it was found that 
more than half had at least heard of BC prior to the study. It was also found that 3 participants 
had a strong understanding of the technology, 1 had a good insight into it while 3 had an idea of 
the technology. It is clear from this research that BC has a long way to before it recognized as a 
potential data management solution in clinical research. The limited survey approach and limited 
number of participants reduced the capacity to enable a conclusive answer to meet this research 
objective.  
The final research objective was: 
• To determine the suitability of Blockchain in addressing the key issues surrounding 
clinical data integrity from a clinical data management perspective through quantitative 
and qualitative research  
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This objective represented the primary research outcome. The general consensus gleaned from 
responses were generally favorable towards the application of BC. Respondents stated how real-
time accessibility that BC offers could significantly improve the integrity of data due to the 
immutability and traceability that BC offers. Participants generally stated how stakeholders, 
including the patients would benefit from having BC-enabled clinical trials. BC posses the 
architectural structure to meet the numerous concerns that were found from both primary and 
secondary research. However, there is much research and studies to be conducted in the future to 













A mixed methods approach was conducted as part of this research study to examine the impact 
of BC on clinical trial data integrity. The first objective of this research was to delve deeper into 
the predominant clinical data issues that are cited to be ubiquitous throughout the clinical 
research industry. Clinical data issues such as quality, transparency, traceability, auditability and 
real-time accessibility to data were all issues that were regularly encountered throughout the 
secondary research. Through thematic analysis from qualitatively gained data, it was found that 
most of these issues were mentioned by participants as being areas that could be improved 
upon. Correlation with participant responses and what was found in the literature relating to 
clinical data integrity concerns shared similarities. It can be stated that all of these particular 
areas within data management all collectively contribute to the level of integrity and trust that 
can be harnessed from clinical data. Data is such an important aspect to modern day society that 
there must be a foundation of trust embedded within data and this is especially relevant to 
personal health data. Clinical trials embody a fundamental aspect of modern-day medicine and it 
is fundamental that the data produced from them is completely representative of the trial so that 
patients receive the necessary care and treatment they require. While primary research 
confirmed the existence of these issues, it did not highlight why or how these issues arise, 
however despite this, primary data gave an insight into some of the issues that occur and 
highlighted areas of primary concern such as data quality and transparency.  
It is evident from primary research that BC has a long way to go in terms of awareness and 
understanding of the technology as was expected. There still remains a great deal of ambiguity 
surrounding the technology such as its association with cryptocurrencies while there are 
numerous challenges to overcome such as increasing the perceptiveness of clinical researchers 
and patients to the technology’s potential and this represents one of the conclusions from the 
research. Without actually testing BCT within clinical trials it is not possible to say from this 
research that it will solve the extensive clinical data integrity-related issues encountered in the 
clinical industry. However, it can be concluded from the research that there is general favour for 
its potential applicatory benefits but there are many challenges and obstacles the technology 
must first overcome. The final research objective was to determine the suitability of Blockchain 
in addressing the key issues surrounding clinical data integrity from a clinical data management 
perspective Until these challenges are addressed it not possible to conclude the final research 
objective. However, until these Blockchain-related challenges are recognised, addressed and 
solved it is not possible to conclusively state that BC is suitable for addressing the clinical data 
integrity concerns.  
In general, the purpose of the research was met. Clinical data issues were identified through 
secondary research and correlated with the primary research of this study, awareness and 
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understanding of BC by clinical research data management professionals was assessed and the 
suitability of BC was recognized from both primary and secondary research. The purpose of this 
study can be considered justified as BC has all the fundamental characteristics built into its design 
to meet the demands required to improve the integrity of data produced throughout clinical trials. 
The trust placed in clinical data is fundamental to the advancement of safe medicine for patients 
and this is true now more than ever as clinical data is being produced in vast quantities spread 
across multiple complex data streams that will only increase over time. BC not only has the 
potential to improve the integrity of the data but can also build trust back into clinical research. 
There is significant further test studies and research to be carried out opening up vast areas of 
potential future research for its applicability within clinical research. 
 
These are the final conclusions of the study: 
• There are extensive data-related issues within clinical research that contribute to the lack 
of integrity in the resulting data 
• There are many potential uses for Blockchain within clinical trials beyond addressing 
integrity 
• Blockchain could be used to improve the trust patients have in enrolling within clinical 
trials and sharing their data with clinical researchers 
• There is a slight lack of awareness and understanding of Blockchain which could inhibit 
its implementation  
• There are numerous challenges currently inhibiting its application within clinical research 
and these need to be addressed 
•  If BC overcome the challenges facing it, it could overhaul how clinical data is shared, 
managed and stored and could usher in an era where clinical data is “trustless” 
 
 Limitations of the Study 
Following completion of this study there were various alternative directions the researcher could 
have taken to answer the research objectives. As mentioned in chapter 3 of this research, it was 
the researcher’s intent to carry out qualitative interviews to discuss first-hand the issues that 
impact upon clinical data integrity. For this strategy an interpretivist philosophy would have been 
adopted to gain qualitative data to provide deep insights into the issues at hand based upon 
personal experiences and industry-based knowledge in a primarily inductive nature. Given more 
time a purely qualitative inductive approach would be taken and following that based upon the 
findings a quantitative deductive survey would be dispersed resulting in a sequential exploratory 
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mixed methods design. This would allow emphasis to be placed upon the qualitative exploration 
of data integrity issues and objectives pertaining to BC and themes discovered would be used to 
form the quantitative research.  Results from these two methods could be then be integrated and 
triangulated to provide further depth and understanding to the research while providing more 
conclusive results.  
The first objective of this study was to gain a deeper understanding to some of the key issues 
surrounding clinical data integrity. Data gathered from secondary research suggested primary 
areas of concern, however implementing the survey method was limited in scope to delve deeper 
into these issues as it was not possible to conduct follow up questions in the self-completed 
survey. Conducting semi-structured interviews may have allowed for a more comprehensive 
analysis of the problems facing clinical data and further exploration of the implementation of the 
technology. Ultimately due to the methodological approach the study failed to thoroughly meet 
the research objectives. The sampling method was also limited as although it was not the intent 
to present the data representatively of the population of those involved with clinical data 
management, a larger more diverse sampling method would have provided more conclusive data. 
Participants who did not have prior knowledge of BC called into question the reliability of the 
research strategy and this was evident within the survey as there were inconsistencies in the data 
identified that were associated with BC awareness and understanding. It is therefore reasonable 
to presume that there were elements of uninformed decisions from certain participants and/or bias 
introduced in favour of BC throughout the survey that influenced participants decisions. In 
addition, some questions could not be considered reliable as a degree of ambiguity in responses 
was noted. Some questions lacked relevancy to the overall research objectives.  
Upon completion of the survey process, select questions were identified that had limited scope in 
addressing the research objectives and provided irrelevant data. These questions could have been 
more integrative of BC and clinical data integrity. A further limitation was the overall scope of 
the research. Data integrity could be considered a broad umbrella term that encapsulates numerous 
data issues and it is therefore possible that the research could have been narrowed in scope to 
identify one particular area of interest in which to apply BCT. One further limitation was the 
overall scope of the research. It may have been prudent to select one of the areas of clinical data 
concerns such as data traceability for example and focused on how BC could be implemented to 
improve that specific area. Trying to address the impact on clinical data integrity overall increased 
the breadth of the research beyond the time allowances that were given for the research to be 




The implementation of Blockchain technology within clinical trial research holds many potential 
benefits for improving the transparency, traceability and overall integrity of clinical data, 
however, there are numerous challenges that face the coalescence of the two. Challenges such as 
personal data security, compatibilities of BC with current clinical data management systems, 
forcing all stakeholders to use BC as well as regulatory compliancy issues all face the implantation 
of the technology. To expand upon this research, the challenges that face BCs application with 
clinical trial research should be explored in greater detail. It is evident from this research that 
there is an interest in the technology for meeting the issues of data integrity, however, BC also 
holds additional beneficial applicatory purposes for areas such as clinical trial recruitment, 
protocol management, real-time patient monitoring and shared clinical trial research in a central 
repository. Throughout the secondary research carried out as part of this research there was 
seldom mention of any analysis or studies carried out on the obstacles that face the application of 
the technology and this would be a very promising area for further research. One particular area 
which would be worth pursuing is how to ensure BC is compatible with GDPR while storing and 
sharing personal clinical data as this was a theme that arose in both primary and secondary 
research. Another potential area is the use of BC in sharing clinical data across multiple 
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 Appendix 1: Social Media (Facebook and LinkedIn) Text Invitation  
 
Hi (name), 
My name is Karl Cullen. I an Irish Masters student currently pursuing a Masters in 
Pharmaceutical Business and Technology in Griffith College, Dublin in association with the 
Innopharma Faculty of Pharmaceutical Sciences.  
My research topic is on “The Impact of Blockchain Technology on Clinical Trial Data 
Integrity”. My research involves gaining a deeper understanding into some of the predominant 
issues that contribute towards clinical data integrity within clinical trial research and how a new 
and emerging technology such as Blockchain could affect it. As part of my research, I must 
carry out quantitative and qualitative analysis. This consists of an online survey that will take 
approximately 10-15 minutes to complete. My research involves seeking those who are 
primarily involved with data management within clinical trials. I would greatly appreciate and 
value your input and participation.  
As Blockchain is a relatively new technology within this industry it not necessary that you 
possess prior knowledge of the technology as part of my research is to evaluate the awareness of 
the technology.  However, if you have do not have prior knowledge, a short un-biased 
description of Blockchain and its main characteristics will be included into the introduction to 
the survey.  
If you would like to participate in this study, please let me know and I will provide a link to the 
survey. My email is: Karl.cullen3345@gmail.com 
Kind regards,  
Karl Cullen  
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 Appendix 2: Privacy and Consent Agreement 
 
This study is part of the fulfilment of a MSc degree in Pharmaceutical Business & Technology 
with Griffith College Dublin. 
The main purpose of this research is to examine how a new and emerging technology known as 
Blockchain could impact clinical trial data integrity.  
By answering the following questions, you are agreeing to participate in this research. Please 
note that all personal information will be kept confidential and will not be cited within the 
research and answers will be used purely for academic reasons only. All information collected 
will be treated as per GDPR regulations. If you do not wish to answer a question it is not 
mandatory, and you skip the question if you wish.  
By participating you are agreeing that: 
- I am voluntarily participating in this research 
- I understand that my answers will be used for academic purposes only and no personally 
identifiable  
  information will be shared 
- I understand that participation is not mandatory, and I can exit the survey at any point I wish 
- I did not and do not expect to receive any form of monetary incentive or otherwise to 
participate  
- I can request a copy of my answered survey upon completion if I so wish 
- I am free to contact the researcher with any questions I might have  
- I understand that all questions asked are voluntary and I can choose not to answer a question if 
I so wish 
I have read and understood the prior information and agree to participate in this study.  
 
Your time and participation is greatly appreciated, if you have any future questions you can 







 Appendix 3: Original Text Invite (LinkedIn) for Qualitative Interview  
 
Hi (name),  
My name is Karl Cullen. I am a MSc student pursuing a Masters in Pharmaceutical Business 
and Technology in Griffith College, Dublin. My research project is on “The Impact of 
Blockchain Technology on Clinical Trial Data Integrity”. My research involves gaining a 
deeper understanding into data management within clinical research and how a new and 
emerging technology such as Blockchain could affect it. As part of my research, I must carry 
out qualitative analysis in the form of structured interviews. My research involves those who are 
primarily involved with data management in clinical trials and I would like to have a short 
interview with you, if possible (by telephone or zoom), which will take approximately 15 
minutes. My research involves awareness of this technology, so it is not necessary to have any 
prior knowledge about Blockchain beforehand. My research participants of interest are Clinical 
Data Managers and/or Clinical Research Coordinators.  
Before considering participation, it should be noted that no personal identifiable information 
will be shared and although an audio recording will be kept for the interview, it will be used for 
transcription purposes and will subsequently be destroyed post transcription. Under no 
circumstances will your identity be revealed or shared.  
I would kindly request your participation for this study. If you like to participate in this 
research, I would be happy to facilitate a date and time at your convenience and can make the 
necessary arrangements  
If you have any questions please do not hesitate to reply to my email address: 
Karl.cullen3345@gmail.com or you can reply to me here on LinkedIn.  
Kind regards  
Karl Cullen  
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